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SEX-BIAS IN LUPUS-PRONE (NZBxNZW)F1 MICE: THE INTERPLAY OF 
GR1+CD11b+ CELLS, TESTOSTERONE AND GENETICS 
 ABHISHEK TRIGUNAITE 
ABSTRACT  
 
Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disorder 
predominantly (9:1) targeting females. Currently, there is no cure for SLE and also there 
is a lack of disease predicting biomarkers. The major aim of my research is to determine 
the cellular basis of the sex bias in SLE and subsequently facilitate the development of 
better therapeutics and biomarkers for the disease.  In (NZBxNZW) F1 mice a similar 
female bias is observed as in humans and testosterone is shown to be protective against 
lupus-like disease development, but the mechanism is not well understood. 
We found higher levels of Gr1
hi
CD11b
+
 myeloid cells in (NZBxNZW) F1 male mice as 
compared to females. Interestingly, Gr1
hi
CD11b
+
, as well as Gr1
low
CD11b
+
, cells have 
been characterized as granulocytic and monocytic myeloid derived suppressor cells 
(MDSCs), respectively. Hence, we hypothesized that - Gr1
hi
CD11b
+
 cells suppress B cell 
activation and differentiation and protect against lupus-like disease.  
We report here that Gr1
hi
CD11b
+
 cells from pre-pubertal male and female BWF1 
significantly suppress in vitro cytokine-mediated B cell differentiation into plasma cells. 
In vivo depletion of Gr1
+
 cells leads to significantly elevated levels of ANA in male 
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(NZBxNZW)F1 mice. Additionally, Gr1
hi
CD11b
+ 
cells are regulated by male sex 
hormone.  
Our findings also show that Gr1+ cells suppress antibody response to antigen challenge 
in (NZB x NZW) F1 male mice through inhibition of T follicular helper (TFH) cells and 
germinal center formation. The identification of testosterone dependent immune-
suppressive cell population in lupus-prone mice can, in part, explain the protective role of 
testosterone in lupus-like disease development.   
We also examined the hormone independent contribution of male versus female immune 
system in development of lupus like disease in (NZBxNZW)F1 mice. The results of these 
studies indicate that the intrinsic auto-immune capabilities of the female (NZBxNZW)F1 
hematopoietic cells can override the protective effect of testosterone. 
Further studies are required to identify the correlation between immune system 
development and sex hormones with specific emphasis on the identification of molecular 
targets that may better serve as therapeutic and preventive tools for management of SLE 
and provide a better quality of life for people suffering from this disease. 
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CHAPTER I 
 
INTRODUCTION 
 
1.1 Introduction to Systemic Lupus Erythematosus (SLE) 
 Systemic Lupus Erythematosus (SLE) is a prototypical systemic autoimmune 
disease and it affects multiple organs and organ systems throughout the course of the 
disease(1). According to the Lupus Foundation of America there are 1.5 million SLE 
patients in America and more than 5 million patients worldwide. SLE has been a well-
known immune disorder for more than a hundred years and the first published report of 
lupus dates back to 1856. It was later in the nineteenth century that the neoclassical era of 
lupus research began when Kaposi first described the systemic nature of the disease in 
1872. Till now there is no treatment for SLE.  
            SLE is characterized by a wide variety of clinical symptoms which may vary from 
one individual to another. Such a wide array of symptoms makes the early diagnosis of 
SLE and the management of its clinical manifestations very difficult. In order to help in 
the early and easy diagnosis of SLE, the American College of Rheumatology has put 
 2 
 
forth a list of eleven characteristic symptoms of SLE (Table 1.1) and an individual is 
considered to have active disease if he or she is positive for any four of the eleven 
symptoms. Some of the most common symptoms are- Malar or the Butterfly rash, serum 
antibodies against nuclear antigens (dsDNA, histone and chromatin), kidney disorder and 
arthritis (1). The American College of Rheumatology has also developed a system for 
measuring the severity of the disease known as SLE. 
Table 1.1 Clinical symptoms of SLE. 
http://www.lupusresearchinstitute.org/lupus-facts/lupus-diagnosis 
Disease Activity Index (SLEDAI) which is based on the classical symptoms used for the 
diagnosis of SLE. There are certain other disease indexes which are in clinical use to 
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predict long term mortality from lupus like disease. A significant gap in the knowledge of 
pathogenesis of SLE is the lack of early disease predicting markers. 
1.1.2 Clinical manifestations of SLE 
 SLE earns the title of a prototypic systemic autoimmune disease from the fact that 
the disease can affect a wide array of organ systems.  As shown in Table 1.1, SLE can 
manifest in many different forms. SLE is a chronic immune disorder characterized by 
systemic inflammation leading to renal, dermatological, hematological, cardiovascular, 
neuropsychiatric and musculoskeletal disorders (Figure 1.1). The distribution of the 
symptoms among the affected population is variable and the extent of organ damage also 
varies from patient to patient. SLE proves to be a very complicated disease to treat as it 
follows a remitting and relapsing course. Depending on the organ/organ system involved 
in the pathology of SLE, it can be fatal in many cases.  
 4 
 
 
Figure 1.1 Clinical manifestations of SLE: Various organs and organ systems are 
affected in SLE leading to different symptoms and organ damage. Adapted from (2). 
One of the prime examples of fatal organ pathologies is the renal failure in SLE patients 
due to deposition of IgG immune complexes (IC) within the glomeruli followed by 
complement fixation.  Among lupus patients SLE is the most common cause of death, 
occurring in 34%, followed by infection (22%), cardiovascular disease (16%), 
cerebrovascular disease (6%), and cancer (6%) (3). SLE has been shown to be the 
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number one cause of heart failure in young women. To summarize, SLE is a multi-
faceted disease with various manifestations and organ involvement and can often lead to 
fatality. 
1.2 Current therapies for SLE and Limitations:  
SLE is a very heterogeneous autoimmune disease and presents a challenge to be 
clinically treated. Advances in understanding the molecular, genetic, and pathological 
aspects of SLE in animal models have improved the treatment regimens in recent times 
but there are still many complexities in treating the human disease. Therapies for treating 
SLE can be broadly divided into two major categories - 1) Therapies aimed at systemic 
immune-suppression and 2) Therapies targeting specific cells and molecules of the 
immune system (4).    
1.2 (A) Systemic Immunosuppression: 
Common treatment regimens for SLE involve the use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) such as– naproxen, ibuprofen or, corticosteroids like prednisone targeted 
at symptomatic relief during mild flairs of the disease. There have been studies which 
show a beneficial effect of anti-malarial drugs used in combination with NSAIDs in 
preventing and ameliorating mild manifestations of SLE (5,6).  Other more aggressive 
therapies for severe SLE manifestations involve stronger and broader spectrum immune-
suppressive agents like cyclophosphamide (7), azathioprine, Micophenolate mofetil 
(MMF) and methotrexate (8). Most of these drugs target pathways of de novo synthesis 
essential for cell division and thereby minimize the generation of new auto-reactive T and 
B cells. Some of these drugs are even used in a combinational manner to improve 
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outcomes in patients. For example, MMF and cyclophosphamide used in combination has 
been shown to improve renal function in SLE patients (9). However, there are side effects 
of these therapies which predominantly manifest in form of leukopenia (decrease in 
numbers of circulating leukocytes), gastro-intestinal disorders, oral ulcers, nausea, 
vomiting and susceptibility to opportunistic infections (4). Different therapies have 
shown various levels of success but there is a lack of a set treatment regime with wide 
spread benefits and fewer side effects. 
1.2 (B) B cell targeted therapies: 
In recent years, the use of monoclonal antibodies against specific immune components, 
cytokines and cell types has emerged as alternative therapies for SLE. The advantage of 
these therapies over systemic immune-suppression is a higher degree of specificity and 
fewer side effects. The most attractive target for cell based therapies over the years has 
been B cells as B cells produce pathogenic auto-antibodies leading to most of the 
complications seen in SLE patients. Most of the B cell targeted therapies are either aimed 
at B cell surface specific antigens for directly eliminating pathogenic B cells or 
modulating B cell activation and survival signals. One of the earliest attempts at B cell 
therapies came in 1997 when rituximab, a chimeric murine/human monoclonal antibody 
(mAb) against B cell surface specific antigen CD20 was approved by the US Food and 
Drug Administration (FDA) for use in humans  (10,11). In the following years other anti-
CD20 mAb like atumumab, ocrelizumab and veltuzumab came into existence. 
Unfortunately, anti-CD20 mAb either have failed to clear the safety standards to be used 
in humans or failed to meet the end point requirements (4).  
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Another approach to B cell based therapies are mAb targeting the B cell receptor (BCR) 
or co-stimulatory molecules. Eprauzumab is a mAb against B cell surface specific 
antigen CD22 which modulates BCR signaling causing a decrease in B cell numbers by 
35-45% (12) and has been shown to have positive results in phase IIb SLE trial. 
Abetimus is a mAb which binds to BCR and induces anergy (functional inactivation) of 
B cells. However, none of these mAb has not been approved for clinical use due to lack 
of sufficient data or efficacy (4,13).  
1.2 (C) B cell survival signal targeted therapies: 
The last category of B cell directed mAb are aimed at blocking B cell survival signals and  
co-stimulatory molecules required for activation and differentiation of B cells into 
antibody producing plasma cells. B cell activating factor (BAFF) is a soluble B cell 
survival factor that binds to its receptors TACI (transmembrane activator and calcium-
modulator and cyclophilin-ligand interactor), B-cell maturation antigen and BAFF 
receptor. Increased BAFF levels have been associated with disease activity in SLE 
patients and have been shown to be correlated to disease severity (14-16). Belimumab is 
a humanized mAb against soluble BAFF that prevents the binding of BAFF to its 
receptors on B cell surface. Belimumab showed very promising results in clinical trials 
and was very well tolerated with a high efficacy. There was a marked decrease in the 
total number of B cells, plasmablasts, and IgG, IgA, IgM and IgG anti-ds DNA titers 
after treatment with Belimumab (17,18). Belimumab earned the distinction of being the 
first FDA approved (2011) therapy for SLE in over 50 years. Another mAb limiting B 
cell survival is Atacicept, directed against TACI, the receptor for BAFF and APRIL 
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(another B cell survival signal) leading to reduced serum Ig; however, one side effect is 
increased susceptibility to infections in treated individuals (19). 
1.2 (D) Co-stimulatory molecule targeted therapies: 
Naïve B cells need co-stimulatory signals from T cells to differentiate and proliferate into 
plasma cells, making co-stimulatory molecules a viable target for SLE therapy. B cells 
need engagement of CD40 cell surface antigen with its ligand CD40 ligand (CD40L) in 
order to undergo a germinal center reaction and become antibody secreting plasma cells. 
Blocking of the CD40-CD40L pathway was shown to be beneficial in murine models of 
lupus (20,21). Additionally, mAb against CD40L have been used in clinical trials of SLE 
(19,22) but have not been sufficiently effective. Further studies and trials are required to 
understand the exact mechanism of this therapy. Alternatively, blocking of another co-
stimulatory pathway involving B-cell coligands B7-1 and B7-2 with a fusion protein of 
extracellular domain of cytotoxic T lymphocyte-associated antigen 4 receptor (CTLA4) 
has shown promising results in mouse models of lupus (23). Figure.2 summarizes the 
different B cell directed approaches with their targets.  
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Figure 1.2 B cell based therapeutic targets for treatment of SLE. B cell costimulatory 
molecules and receptors for the survival factors BAFF and APRIL are shown as well as 
cell surface molecules being targeted therapeutically. The therapeutic agents are 
identified along with their targets. Adapted from (4).  
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1.2 (E) Alternative therapies:  
There are studies showing the efficacy of anti-cytokine therapies in treatment of lupus 
patients. Neutralizing disease promoting cytokines TNF, IL-1, IL-10, IFN-α and IL-6 has 
shown promising results in mouse models of lupus and other autoimmune diseases 
(reviewed in detail in (4)). Additionally, there are studies showing the beneficial effect of 
blocking specific kinases involved in immune cell function as a target for treating 
autoimmune diseases. Specifically, use of small molecule inhibitors of Spleen tyrosine 
kinase (Syk), responsible for aberrant T cell signaling in lupus, has been shown to 
suppress disease in lupus prone (NZBxNZW) F1 mice (24). There are ongoing clinical 
trials for Syk inhibition and it could be a promising therapy for SLE (25).   
To summarize, there are various emerging therapeutic targets for treatment of SLE, but 
only a few have shown promise with high efficacy and few side effects. The most 
common side effect of current therapies is an immune-compromised state of the treated 
individuals leaving them highly susceptible to opportunistic infections and poor quality 
of life. There is no permanent cure for SLE to date and there is a need to develop more 
specific therapies with lesser side effects. 
1.3 Overview of autoimmunity and triggering mechanisms:  
Classically, autoimmune diseases are defined as the response to non-foreign antigens 
mediated by T cells and antibody secretion by B cells. Autoimmunity could manifest in 
an organ or tissue specific manner or can affect multiple organs and organ systems.  
According to National Institute of Allergy and Infectious Disease (NIAID), there are 80 
defined autoimmune diseases and the underlying cause of all the autoimmune disease is a 
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dysregulated immune system. Autoimmunity arises from the dysregulation of the 
immune system where the body’s defense mechanism goes into uncontrolled overdrive 
and attacks self-tissue. It is notable that both the innate (non-specific) and acquired 
(specific) branches of the immune system contribute to the development of autoimmunity 
with specific cell types playing distinct roles (discussed in more detail in section 1.4). 
Hence, it becomes critically important for the immune system to be able to precisely 
differentiate between self and non-self-antigens. The importance of identifying self and 
non-self was recognized as early as the 1950s when Medawar and colleagues 
demonstrated with elegant experimental approaches the very first evidence of immune 
tolerance (26). Any breach in immune tolerance can lead to immune-dysregulation and 
autoimmunity.  
Several theories and factors explain the initiation of autoimmunity resulting from 
immune dysregulation. In this section, different triggers of autoimmunity and the 
underlying causes will be discussed. 
1.3.1 Tolerance to self-antigens: 
One of the most fascinating features of the immune system is it’s ability to clearly 
distinguish between self-and non-self-tissue, which provides critical cues to immune cells 
as when to mount an immune response and when not to. It is appreciated that even after 
maintaining a tremendous ability to mount an immune response against an immense 
number of foreign antigens; the immune system preserves its specificity and tolerance 
towards self-antigens. The most important cell types are equipped with antigen-specific 
receptors and have the ability to design their receptors for a wide array of antigens, 
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notably T cells and B cells. Most of the time the generation, remodeling and retention of 
the T cell receptor (TCR) and BCR and subsequent deletion of self-reactive T cells and B 
cells works flawlessly, but there are occasions when the system is leaky and may lead to 
non-desirable outcomes in terms of self-reactive T and B cells.  T cells and B cells, on 
recognizing an antigen and receiving the appropriate co-stimulatory signals, can undergo 
clonal expansion and mount an immune response and recruit innate immune cells to take 
part in the ongoing immune response. If the T and B cells encounter and recognize a self-
antigen, it can lead to deleterious anti-self-immune response that can prove to be very 
damaging. Thus it becomes critically important to have safety check points at the 
developmental level for elimination of self-reactive T and B cells.  
1.3.1 (A) Central tolerance 
The process of central tolerance is aimed at eliminating any self-reactive lymphocytes (T 
and B cells) at an early developmental stage. Although both T cells and B cells arise from 
a common Hematopoietic Stem Cell (HSC), their development takes place in different 
lymphoid tissues (27,28). T cell development takes place predominantly in thymus and B 
cells undergo development in the bone marrow (BM). Thus, the process of central 
tolerance takes place in lymphoid tissues – thymus (T cells) and bone marrow (B cells). 
During T cell development in the thymus, T cells undergo a sequential series of 
differentiation steps. T cells start as CD4
-
 CD8
-
 (Double negative) which become CD4
+
 
CD8
+
 (Double positive) and finally mature into CD4
+
 or CD8
+
 (Single positive) cells 
(29). There are distinct selection processes that the developing T cells must undergo. 
Firstly, the double positive (CD4
+
 CD8
+
) T cells undergo positive selection. Only the T 
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cells that can recognize either peptide/MHC class I or peptide/MHC class II complexes in 
the thymic cortex receive a positive signal to continue in the maturation process, while 
the remaining T cells with a non-viable TCR are eliminated by the process of apoptosis 
(28). After undergoing positive selection for a functional TCR, T cells are either 
committed to CD4 or CD8 lineage and later on form the majority of peripheral T cell 
population (30).  The next step in T cell development, negative selection, is very critical 
to the induction of tolerance and involves elimination of T cells bearing a self-reactive 
TCR. The most important molecule in negative selection of T cells is the transcription 
factor autoimmune regulator (AIRE). AIRE is expressed by medullary thymic epithelial 
cells and it controls the expression of numerous self-antigens in medullary thymic 
epithelial cells (31,32). These self-antigens are presented to developing T cells in 
complex with MHC and T cells with high reactivity to self-antigen/MHC complex are 
deleted (33,34). Some T cells with intermediate reactivity to self-antigen/MHC 
complexes evade the negative selection process and go on to become regulatory T cells 
(Tregs) (described later in section 1.5.2)  (32,33). Hence, AIRE plays a very important role 
in negative selection of self-reactive T cells, development of Tregs (regulatory T cells) 
from some self-reactive T cells and induction of central tolerance. The critical role of 
AIRE in maintenance of central T cell tolerance has been shown in both humans and 
mouse models where a mutation or deficiency of AIRE leads to severe autoimmune 
diseases (35). 
B cell central tolerance occurs in BM during B cell development and differentiation. The 
central B cell tolerance is mediated either by the deletion of self-reactive B cells or by 
receptor editing (36,37). Immature B cells reacting with high affinity to self-antigen 
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undergo apoptosis (deletion). This deletion mechanism may be crucial when all receptor 
editing options are exhausted (37). B cells express recombination activating genes (Rag) 
which are responsible for generation of BCR diversity and receptor editing. After 
generation of a viable BCR, immature B cells in the bone marrow cease to express Rag 
genes. Immature B cells that encounter multivalent self-antigens revert to pre-B cell-like 
phenotype, re-express Rag genes, and induce κ light chain gene rearrangements (if 
necessary, λ). New Vκ-Jκ rearrangements, involving upstream V segment and 
downstream J segment, delete the original Vκ-Jκ rearrangement that had produced a self-
reactive light chain, resulting in newly generated B cells that have a novel light chain that 
is no longer reactive to self-antigen. These immature B cells then migrate to the periphery 
where they mature into IgM- and IgD-bearing B cells (38-40). The importance of Rag 
genes in B cell central tolerance is confirmed by studies showing that mutations in Rag 
genes correlate with development of autoimmunity in humans as well as mouse models 
(37). 
Hence, the process of central tolerance ensures that the auto-reactive T and B cells are 
eliminated during development; but still, some of the auto-reactive lymphocytes escape 
negative selection and enter the periphery. There are further check points to eliminate 
such cells in the periphery but sometimes the breach of central tolerance can lead to 
autoimmunity.  
1.3.1 (B) Peripheral tolerance: 
There are certain immune mechanisms that are in place to deal with the auto-reactive B 
and T cells that evade central tolerance check points and enter the periphery. The main 
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players in T cell peripheral tolerance are Tregs. Tregs are characterized by the expression of 
transcription factor Foxp3 which mediates their immune-suppressive function. Tregs 
deprive effector T cells of antigens by forming long-lasting interactions with antigen 
presenting dendritic cells (41) and thereby dampen the immune response. Mutations in 
Foxp3 gene have been associated with development of autoimmunity in both humans and 
mice (35,42). 
B cell peripheral tolerance is mediated by induction of anergy, clonal deletion of auto-
reactive mature B cells, direct suppression by Tregs and clonal ignorance (37). However, 
anergy seems to be the most dominant mechanism involved in B cell peripheral tolerance. 
Anergy is the process of maintaining auto-reactive B cells in a state of 
hyporesponsiveness and making them incapable of reacting to self-antigens. B cell 
anergy is mostly mediated by the inability of self-reactive B cells to respond to antigen 
coupled to BCR. The most common mechanism for B cell anergy is the lack of co-
stimulation by T cells(43). Defects in silencing auto-reactive B cells in the periphery may 
lead to adverse outcomes and autoimmunity. 
1.3.2 Mechanisms involving innate immune cells: 
Innate immune cells form a very important part of the immune system and play an 
instrumental role in generating an appropriate immune response. Innate immune cells 
perform various functions like immune surveillance, antigen presentation and clearance 
of cellular debris. Dysregulation of innate immunity can lead to aberrant activation of 
acquired immune cell subsets and may lead to autoimmunity (44). In this section the role 
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of innate immune cells and the underlying mechanisms that may trigger autoimmunity is 
discussed.  
1.3.2 (A) Dendritic cells and toll like receptors (TLRs): 
Dendritic cells (DCs) are the most potent antigen presenting cells of the immune system 
and play a crucial role in mounting immune responses. One of the striking features of 
DCs is the expression of membrane bound Toll-like receptors (TLRs) which are pattern 
recognition receptors (PRRs) capable of responding to both endogenous as well as 
exogenous antigens. Currently 13 members of TLR family have been identified, out of 
which TLR1 to TLR10 are functional in humans (45). TLRs are capable of recognizing 
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular 
patterns (DAMPs) (46). PAMPs are evolutionarily conserved exogenous molecules like 
lipopolysaccharide (LPS), peptidoglycan and bacterial and viral nucleic acids. DAMPs on 
the other hand are endogenous molecules like heat shock proteins which are released 
during tissue injury and cell death (47). TLR3, TLR7, TLR8 and TLR9 are found on the 
endosome in DCs (dendritic cells) and recognize viral nucleic acids. Upon binding to 
their respective ligands TLRs initiate signaling cascades resulting in DC activation, 
upregulation of co-stimulatory molecules (CD80, CD86 and MHCII) and release of pro-
inflammatory cytokines (IFN-α, IL-6)  capable of inducing T cell activation (48).  It has 
been shown in a number of autoimmune diseases, like SLE, type I diabetes and multiple 
sclerosis, that over-stimulation of TLRs can lead to abnormal activation of T and B cells, 
resulting in autoimmunity (44). Specifically, SLE is characterized by production of anti-
nuclear antibodies and the presence of circulating immune complexes containing DNA 
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and RNA. It has been shown that CD32-mediated uptake of these immune complexes 
containing DNA and RNA by DCs and the subsequent activation of TLR7 and TLR9 
play an important role in pathogenesis of SLE (49,50). 
Additionally, DAMPs can also stimulate TLRs and there is a strong possibility that it can 
lead to autoimmunity via DC-mediated activation of T and B cells in response to 
mechanical tissue injury or necrosis (51).  
1.3.2 (B) Defective clearance of cell debris: 
As discussed above, circulating immune complexes and DAMPs can lead to over- 
stimulation of DCs, resulting in a break of tolerance and induction of autoimmunity. 
Hence, efficient clearance of cell debris is required to make sure that there is not an 
excess of TLR stimulants present in the system. There is defective clearance of apoptotic 
bodies in mouse models of SLE (52). Also tissue damage resulting in necrosis leads to 
abundance of auto-antigens in circulation. Macrophages are the major scavenging cells of 
the immune system responsible for clearing cellular debris and apoptotic bodies. It has 
been shown in SLE patients that there is defective clearance of apoptotic bodies by 
macrophages which in turn causes prolonged exposure to auto-antigens and predisposes 
one to auto-antibody production (53).    
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1.3.3 Environmental factors: 
Autoimmunity could be triggered by environmental factors, including exposure to 
microorganisms and diet. Although the exact mechanisms are not well understood, it has 
been shown in various animal models that modulation of gut microbiota can alter the 
susceptibility to autoimmune diseases (54). The composition of gut microbiota can have 
pro-inflammatory or anti-inflammatory effects depending on the host immunological 
state (55). In a mouse model of experimental autoimmune encephalomyelitis (EAE) 
Bacteroides fragilis polysaccharide A protects from disease by inducing Tregs
 
(56). 
Similarly, in (NZWxBXSB)F1 model of lupus, caloric restriction has a protective effect 
on lupus-like disease development (57). On the other hand, there is emerging evidence 
that engagement of TLRs with gut microbiota DNA can alter the course of autoimmunity 
(58). Another interesting theory linking the exposure to microorganisms and development 
of autoimmunity is the Hygiene Hypothesis. This theory postulates that the increased 
incidence of allergic and autoimmune disorders in developed countries could be an 
outcome of a lack of exposure to microorganisms that co-evolved with the human 
population. A sudden exposure to such microorganisms may lead to induction of 
undesired immunological responses leading to autoimmunity (59). As diet and 
composition of gut microbiota go hand in hand it is tough to differentiate the role of each 
factor in modulating immunity.  
Molecular mimicry has also been associated with induction of autoimmunity as it has 
been shown that a lot of viral antigens mimic SLE antigens and can lead to relapse or 
even initiation of SLE (60,61). Specifically, an Epstein - Barr virus (EBV) infection has 
been associated with increase in SLE incidence. It has been demonstrated that antibodies 
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against EBV antigens have cross reactivity to dsDNA which is a major SLE antigen. In 
murine models immunized by EBV antigens the production of anti-dsDNA antibodies 
was enhanced (62,63). These studies provide a clear link between molecular mimicry and 
autoimmunity but further studies are required to elucidate exact mechanism and 
correlation to human autoimmune diseases and infections. 
 Also, the role of genetics cannot be overlooked in shaping the immune system and 
susceptibility to autoimmunity (discussed in detail in section 1.6). 
To summarize, autoimmunity is a very complex process and the exact underlying 
mechanisms triggering autoimmunity are not clear. An autoimmune disease could 
manifest as a result of any of the above mentioned triggers or can be an outcome of a 
combination of multiple factors.  
1.4 Sex Bias in SLE: 
The majority of the systemic autoimmune diseases have a strong female bias but the 
actual basis of the sex bias in autoimmunity is not well understood. In fact studies have 
shown that of all the autoimmune-disease affected individuals, more than 75% are 
females (64,65). SLE has a strong female bias, with a female to male ratio of 9:1 in 
human population. SLE is most prevalent in young women during the child bearing years 
(15-45years) and the incidence of the disease goes down in menopausal women (66). It is 
to be noted that in prepubescent years there is a female bias in SLE but the ratio of female 
to male patients is 3:1. Although fewer men develop SLE, male patients present with a 
more severe form of the disease involving a higher incidence of seizures, more severe 
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renal disease as well as cardiorespiratory disorders as compared to female patients 
(66,67). Over all this suggests that the development and pathogenesis of SLE is different 
between males and females.  
1.4.1 Mouse models to study SLE: 
Many murine models of SLE exist and some of them show a similar sex bias in disease 
development as observed in humans. Commonly used mouse models of lupus are - (NZB 
x NZW)F1 hybrid, B6.Nba2, B6.Sle123,  MRL/lpr, and BSXB/Yaa (68) . All these mouse strains 
spontaneously develop a lupus like disease and mimic a variety of symptoms present in human 
SLE. One of the widely studied spontaneous murine models of lupus, the (NZBxNZW) 
F1 mouse has a strong female bias to the development of lupus-like disease. These mice 
are genetically susceptible to develop a lupus like disease where 100% of the females 
develop disease by 12 months of age whereas only 30% of male mice develop disease 
(69). Interestingly, in the (NZBxNZW) F1 mouse model, lupus like disease is 
characterized by elevated levels of circulating serum autoantibodies to nuclear antigens 
chromatin, histone and dsDNA. These mice also develop renal disease marked by IgG 
immune complex (Ig-IC) deposition within the kidney glomeruli. Glomerulonephritis and 
the extent of renal damage can be measured in terms of proteinuria (70,71).  
(NZBxNZW)F1 is a spontaneous and multigenetic model of SLE and closely resembles 
the sex bias observed in humans. Additionally, (NZBxNZW) F1 mice mimic most of the 
important symptoms of human disease which makes it a valuable tool to study lupus. All 
the research described in this thesis has been performed using the (NZBxNZW) F1 
mouse model of lupus.   
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1.4.2 Role of sex hormones in gender bias in SLE:  
The fact that 9 out of 10 SLE patients are female in their child bearing years and that the 
incidence of disease is lower in prepubescent and menopausal women strongly suggests 
the role of female sex hormones in the pathophysiology of SLE. The incidence of SLE is 
the highest in women during the time of their life when they are exposed to maximum 
levels of female sex hormones. Also the noticeable lower prevalence of SLE in male 
populations indicate that there is a protective role of androgens in the development of 
SLE.  
1.4.2(A) Pathological role of Estrogen in SLE:  
Early studies performed on (NZBxNZW) F1 mice showed that ovariectomy of female 
(NZBxNZW) F1 mice protected them from developing a lupus like disease and treatment 
of castrated male mice with estrogen leads to severe lupus-like disease (72,73). B cells 
are central in SLE as they produce auto antibodies leading to disease pathology. Several 
studies have documented the role of estrogen on B cell development, differentiation and 
tolerance. It has been shown in a estrogen driven model of lupus that elevated levels of 
estrogen lower the threshold for negative selection by up regulating Bcl-2 (anti-apoptotic 
molecule) during B cell development, breaching central tolerance of B cells, thereby 
increasing the number of auto reactive B cells in the periphery (74,75). Additionally 
estrogen can enhance the maturation of B cells (76) and selectively impair the negative 
selection of high-affinity DNA reactive B cells leading to higher numbers of mature 
DNA reactive B cells (77). Estrogen has also been shown to increase the expression of 
the co-stimulatory molecule CD40L on T cells and B cells from lupus patients (78,79). 
Hence, estrogen not only directly pushes B cells towards a pathogenic phenotype, but 
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also aids B cell differentiation and maturation via up regulating co-stimulatory signal 
from T cells.  
1.4.2(B) Protective role of testosterone in SLE:  
Testosterone has a broad immune-suppressive effect on the immune system as is evident 
from the fact that males are more susceptible to infections and cancers as compared to 
females (80). Specifically, in SLE the protective role of testosterone was clearly 
demonstrated in 1970s by Talal and colleagues. In sex hormone manipulation studies in 
lupus prone (NZBxNZW) F1 mice it was shown that male mice were protected from 
disease development by the presence of testosterone as castration resulted in the 
development of lupus-like disease symptoms similar to those observed in age-matched 
female (NZBxNZW) F1 mice. Even more interesting, female (NZBxNZW) F1 mice with 
severe disease showed reduced disease severity and prolonged survival upon treatment 
with testosterone (72,73,81). The protective role of testosterone is not only limited to 
SLE but it has been shown to play a protective role in other autoimmune diseases like- 
EAE and rheumatoid arthritis (RA) (82,83). Likewise, testosterone-replacement therapy 
of Klinefelter’s Syndrome patients led to decreased serum antibody and cytokine levels 
and decreased T and B cell levels (84). It has been documented that SLE patients have 
lower circulating levels of testosterone and higher aromatase activity which can convert 
testosterone to estrogen (85).  
It is evident that male and female sex hormones play a significant role in sexual 
dimorphism observed in SLE and other autoimmune diseases. Estrogen drives 
autoimmunity while testosterone is protective. To a large extent the disease driving 
 23 
 
mechanisms and effects of estrogen on immune cells are well understood. But there is 
gap in knowledge for many years as to how testosterone exerts a protective effect in SLE. 
The mechanisms of testosterone driven protection from SLE are not well understood and 
have been underexplored.  
1.5 Key cellular components in lupus: 
 1.5.1 Role of B cells: 
Most of the organ damage seen in lupus is mediated by auto-antibodies produced by B 
cells, so B cells can be called the drivers of lupus pathogenesis (86). B cell hyperactivity 
is a hallmark of SLE. Naïve B cells from mouse models of SLE have been shown to 
respond very strongly to BCR stimulation as compared to naïve B cells from non-
autoimmune mouse strains (87). B cells from lupus patients have a high expression of 
CD40L, generally expressed only by T cells, indicating that lupus B cells can activate 
other naïve B cells (88). Moreover, the emerging role of B cells as cytokine producing 
and antigen presenting cells can also contribute to their role in lupus progression (89). 
Additionally, there is an accumulation of auto-reactive B cells in the marginal zones of 
spleens in mouse models of SLE (89,90). These auto-reactive B cells have a low 
threshold for tolerance and can play a prominent role in initiating autoimmunity (90). A 
regulatory B cell subset producing IL-10 (Bregs) has been identified but the role of this B 
cell subset is not well understood in the development of SLE (91,92). 
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1.5.2 Role of pDCs:  
Plasmacytoid DCs (pDCs) were first identified as CD11c
-
 immature DCs in human 
peripheral blood (93). As compared with conventional DCs, pDCs express lower levels of 
MHCII, lower levels of co-stimulatory molecules and a reduced ability to stimulate T 
cells (93). In contrast, pDCs are the dominant interferon-producing cells in response to 
most viral infections. In fact pDCs have been shown to produce 200-1000 times more 
IFN-α, in response to microbial challenge, compared to any other cell type, conferring 
these cells an important role in anti-viral and anti-tumor immune responses (94,95). 
There have been several studies showing the crucial role of IFN-α in development of 
lupus like disease in mouse models. In fact IFN-α has been associated with development 
of auto-antibodies and IFN-α receptor deficiency has been shown to protect lupus prone 
mice from developing disease (96,97). There is an elevated level of circulating IFN-α in 
human SLE patients which correlates with disease severity and anti-dsDNA antibodies 
(98,99). Also, peripheral blood cells from SLE patients present with a typical gene 
expression pattern known as an “Interferon Signature” where IFN-α inducible genes are 
upregulated (100,101). A recent study showed that depletion of IFN-α producing pDCs in 
lupus prone B6.Nba2 mice leads to reduced levels of anti-nuclear auto-antibodies (102).  
Since, pDCs are dominant producers of IFN-α, we can speculate that they may play a 
pivotal role in SLE pathogenesis.  
1.5.3 Role of neutrophils: 
Neutrophils are innate immune cells of myeloid origin and arise from the common 
myeloid progenitor (CMP) in the BM in response to specific stimuli including both 
cytokines and growth factors (103). Neutrophils are the most abundant circulating 
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immune cells and form the first line of defense against microbial and fungal infections. 
These cells are short-lived and contain granules rich in anti-microbial proteins to kill 
invading pathogens (104). The disease driving role of neutrophils in SLE has been 
extensively studied and well documented (105), but in recent years there have been 
studies exploring the anti-inflammatory properties of neutrophils in SLE and a variety of 
other autoimmune disorders (106). In the following section, the pro and anti- 
inflammatory role of neutrophils will be discussed in detail.  
1.5.3 (A) Pro-inflammatory role of neutrophils: 
The role of neutrophils in driving SLE has become more evident in recent years and 
various neutrophil driven phenomena have come to light that can aid SLE progression. 
Neutrophils are potent producers of cytokines that can modulate both T cell and B cell 
function and differentiation. Neutrophils produce IL-6, BAFF and APRIL, powerful B 
cell regulators associated with B cell development and antibody production (106). IL-6 
manipulation has been shown to affect lupus pathogenesis in mouse models of SLE (107-
109). BAFF is a B cell survival signal and it has been reported that neutrophil derived 
BAFF leads to elevated T and B cell responses in lupus prone mice (110). APRIL is a 
plasma cell survival signal and BM neutrophils from lupus patients produce APRIL 
(111). Thus, neutrophil derived cytokines can aid B cell differentiation and development 
at an early stage and prolong survival of antibody producing plasma cells. Another 
important cytokine in SLE pathogenesis is IL-21, which is required for GC formation and 
antibody production (112). Neutrophils can produce IL-21 under chronic inflammatory 
conditions and lead to T cell independent B cell activation and differentiation in SLE 
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(113). Finally, neutrophils can also produce IL-17A which has been implicated in 
development of SLE and other autoimmune disease (114). 
Another interesting area of emerging research regarding the role of neutrophils in 
pathogenesis of SLE is NETosis. NETosis is a specialized process of neutrophil death 
where neutrophils form NETs (neutrophil extracellular traps) to trap pathogens and 
subsequently undergo death (115,116). NETs are loaded with anti-microbial proteins like 
myeloperoxidase (MPO) and LL37, along with histones and free DNA and are shown to 
induce IFN-α (key cytokine in SLE discussed in section 1.6) production via TLR9 
crosslinking in pDCs (117). Recently, in SLE patients a subset of neutrophils termed as 
low density granulocytes (LDGs) have been shown to undergo spontaneous NETosis in 
vitro and produce IFN-α (118).  
1.5.3 (B) Anti-inflammatory/immunosuppressive role of neutrophils: 
The very first evidence for the existence of the anti-inflammatory neutrophils came from 
cancer studies. Ly6-G
+
 and Ly6-C
+
 immature myeloid cells were shown to infiltrate 
tumors and to suppress anti-tumor T cell responses in cancer patients (119). Since then 
there have been numerous studies defining the immunosuppressive function and 
mechanisms of these neutrophil like cells. Such cells have been named myeloid derived 
suppressor cells or MDSCs. The regulatory functions of MDSCs and the identification of 
MDSCs as potent immunosuppressive cells were first established in cancer models, 
where the cells act to suppress T cell mediated anti-tumor responses (reviewed in detail 
(120)). MDSCs are further divided into two different categories based on cell surface 
marker expression- Gr-1
high
Ly-6G
+
CD11b
+
(granulocytic MDSCs) or Gr-1
low
Ly-
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6C
+
CD11b
+
(monocytic MDSCs) (121) (Figure 1.3). MDSC subsets isolated from tumors 
have been shown to use reactive oxygen species (ROS), inducible nitric oxide synthase 
(iNOS), and TGF-beta as their main mechanisms of T cell suppression (121-124). The 
role of MDSCs in autoimmune diseases is currently emerging and it has already been 
shown in EAE and type I diabetes that MDSCs can suppress autoimmunity and alleviate 
disease symptoms (125,126).  
 
 
 
 
 
 
 
Figure 1.3 The pathways of MDCS development and differentiation in cancer. 
MDSCs develop from the CMP (common myeloid progenitor) in BM. MDSCs are 
classified as Monocytic MDSCs (Gr1
low
 CD11b
+
) and Granulocytic (Gr1 
high
 CD11b
+
). 
Adapted from (120). 
Monocytic  
MDSCs 
Granulocytic  
MDSCs 
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These studies encouraged us to explore the role of MDSCs like cells in lupus prone (NZB 
x NZW) F1 mice. Interestingly, we found elevated levels of Gr-1
high
Ly- 6G
+
CD11b
+
   and   
Gr-1
low
Ly-6C
+
CD11b
+ 
MDSC like cells in lupus prone male (NZB x NZW) F1 mice as 
compared to female (NZB x NZW) F1 mice and hypothesized that – Higher of levels of 
Gr-1
high
Ly- 6G
+
CD11b
+
 and Gr-1
low
Ly-6C
+
CD11b
+ 
MDSC like cells in lupus prone 
male (NZB x NZW) F1mice may protect them from development of lupus like 
disease. The results of the studies performed to test this hypothesis are discussed in detail 
in ChapterII (Gr-1
high
CD11b
+
 Cells Suppress B cell Differentiation and Lupus-like 
Disease in Lupus-Prone Male Mice; Published in Arthritis and Rheumatism, 2013). 
1.5.4 Role of T cells:  
T cells are indispensable for driving lupus like disease as T cells help is essential for 
formation of germinal centers and B cell differentiation into antibody secreting plasma 
cells (127,128).  There are different functions associated with the various T cell subsets in 
the pathogenesis of SLE. This section will discuss the role of each T cell population in 
SLE.  
1.5.4 (A) Role of TH17 cells:  
TH17 cells are characterized by the expression of the transcription factor ROR-γt and the 
production of the pro-inflammatory cytokines IL-17, IL-21, IL-22, and IL-6 (129,130). 
TH17 cells play an important role in protection against bacterial and fungal infections and 
clearance of pathogens (131,132). TH17 cells have also been associated with the 
induction and development of autoimmune diseases, including SLE (114,132-134). 
Several studies have shown an increase in TH17 cells in both murine models of lupus as 
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well as in patients with SLE. Additionally, the increased circulation of CD4
+ 
TH17 cells 
correlates with disease activity in patients with SLE (131,135). The main cytokine 
produced by TH17 cells, IL-17, works in accordance with BAFF, promoting B cell 
proliferation and differentiation into antibody secreting cells, and ultimately the 
production of autoantibodies (136). The TH17 polarizing cytokine IL-6 is also increased 
in patients with SLE as opposed to healthy controls, and studies have shown that IL-6 
plays a role in B-cell hyperactivity and autoantibody production (131,135,137).  A 
dichotomy exists between levels of TH1 and TH17 in patients of SLE. The TH1 cytokine, 
IFN-γ is shown to suppress TH17 differentiation, and a deregulation between TH17:TH1 
balance has been observed in patients with SLE (131,135). In support of this, a 
significant down-regulation of IFN-γ and reduced levels of TH1 cells have been reported 
in patients with SLE (131,135,138).  However, increased levels of IFN-γ were observed 
in patients with active SLE (135). Overall, TH17 cells play a disease driving role in SLE 
by mostly promoting auto-antibody producing B cells. 
1.5.4 (B) Role of TH1 cells:  
TH1 cells play a crucial role in protecting an individual from infections by bacteria, fungi, 
and viruses (132,139-141). The pro-inflammatory cytokines produced by these cells, 
IFNγ and TNFα/β, stimulate innate and cell-mediated responses, resulting in the 
clearance of pathogens (142). TH1 cells however have been associated with autoimmune 
diseases such as type I diabetes and RA (143,144).  Studies have shown that both levels 
of TH1 cells as well as levels of IFN-γ are decreased in patients with SLE, leading to an 
increase in TH17 cells and a propensity towards disease (131,135,138). Other studies have 
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shown that, among patients with lupus nephritis however, a predominance of TH1 cells is 
observed and promotes renal inflammation (145). Thus, the role of TH1 cells in the 
progression of lupus is not clear. 
1.5.4 (C) Role of TH2 cells:  
The function of TH2 cells is associated with activating humoral immunity and promoting 
IgG1 and IgE class switching, protecting against extracellular pathogens such as 
helminthes (132,146).  TH2 cells secrete IL-4, IL-5, IL-6 as well as the pleiotropic 
cytokine IL-10. Interleukin-10 is best known for its anti-inflammatory effects and 
enhancing the survival and differentiation of B cells (147,148). Patients with SLE have 
been shown to have increased plasma levels of IL-10 (135,137). IL-10 has been shown to 
be over produced by B cells and monocytes in patients with SLE (149), and may act in an 
autocrine or paracrine fashion resulting in B cell hyperactivity. Levels of plasma IL-10 
were also shown to correlate with overall disease activity (135). The effects of IL-10 on 
lupus pathogenesis may result from increased TLR-9 expression on B cells, which has 
been shown to correlate with disease activity and anti-nuclear autoantibodies in SLE 
patients (150).  
1.5.4 (D) Role of Tregs:  
T-regulatory cell (T-regs) are characterized by the expression of the transcription factor 
FoxP3 and surface markers CD4
+
CD25
+
. T-regs are known to produce the cytokines 
TGF-β and IL-10 (132). It has been speculated that T-regs suppress autoreactive effector 
T cells and that a decrease in levels of T-regs may result in the development of 
autoimmune disease; however the role of T-regs in lupus is not fully understood (138). 
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Studies conducted with SLE patients showed a decrease in TGF-β levels both in plasma 
and within the periphery (135) . The increased presence of IL-6 within these patients may 
be inhibiting the induction of T-regs and instead promoting TH17 differentiation and 
lupus initiation (135). 
1.5.4 (E) Role of TFH:  
T follicular helper cells (TFH) are a pro-inflammatory subset of CD4
+
 T cells that are 
required for germinal center (GC) formation and plasma cell differentiation. Germinal 
centers are the sites within secondary lymphoid tissue (spleen and lymph node) where 
mature B cells interact with T cells and undergo proliferation and differentiation, affinity 
maturation and class switching to generate a T cell dependent antibody response. The 
formation of GCs (Figure 1.4) is central to mounting an antibody mediated immune 
response and generation of long lived plasma cells (reviewed in detail in (151). TFH cells 
are defined by the production of IL-21 which promotes GC formation and B cell 
differentiation, expression of the chemokine receptor CXCR5 which allows them to 
relocate to B cell follicles, expression of the transcription factor Bcl-6 and the 
costimulatory receptor ICOS, and high expression of the inhibitory receptor PD-1 (152). 
Within the GC, TFH cells promote somatic hypermutation and selection of high-affinity B 
cells followed by differentiation of long-lived memory or plasma cells. This process 
ensured the development of long-lived humoral immunity (112). TFH cells have been 
shown to be dysregulated in SLE patients (153,154). Increased levels of TFH cells caused 
by TFH dysfunction results in increased GC formation and differentiation of B cells into 
antibody producing cells, leading to the production of autoantibodies (154,155). 
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Figure 1.4 The role of TFH cells in GC formation. Adapted from (152).  
Since, T cells and specifically TFH cells play a crucial role in pathogenesis of lupus via 
GC formation and generation of antibody producing plasma cells, based on our earlier 
findings, we examined the role of Gr-1
+
CD11b
+
 MDSCs like cells on T cell independent 
and T cell dependent antibody responses in lupus prone (NZB x NZW) F1 mice. The 
findings of this study are discussed in detail in Chapter III (Gr1
+
 Cells Suppress T-
Dependent Antibody Responses in (NZB x NZW) F1 Male Mice through Inhibition 
of T Follicular Helper Cells and Germinal Center Formation; Published in The 
Journal of Immunology, 2014). 
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1.6. The role of genetic factors on SLE: 
Like many other systemic autoimmune diseases SLE has a very strong female bias and 
the role of genetics cannot be overlooked in the incidence of SLE. There are strong data 
from mouse and human studies which strongly point towards an important role of 
genetics in the incidence and progression of SLE. One of the major factors is the dosage 
compensation effect of the X chromosome where females (XX karyotype) and 
individuals affected by Klinefelter syndrome (XXY karyotype) are 10 times more 
susceptible to SLE as compared to males (XY karyotype) (156). The role of the X 
chromosome in SLE development was elegantly shown in the pristane induced lupus 
model using Sry-transgenic mice. It was shown that male castrated XXSry mice were 
more susceptible to lupus as compared to XY
-
Sry mice (157). Similarly, BXSB.Yaa mice 
containing Yaa (Y-linked autoimmune accelerator) which is a 4-megabase translocation 
of the distal end of X chromosome onto Y chromosome have exacerbated lupus like 
disease (158-160). One of the genes expressed on the distal end of the X chromosome is 
TLR7 and it has been strongly associated with susceptibility to lupus (161). Some of the 
most detailed insights into the genetics of SLE have come from the New Zealand Black 
(NZB) and New Zealand White (NZW) mixed strains (NZM). The (NZB x NZW)F1 
hybrid develops a lupus like disease with a strong female bias displaying characteristic 
features such as - anti-nuclear antibodies and glomerulonephritis (70), while none of the 
parent strains develop full blown disease (162). Detailed studies lead to the identification 
of two separate susceptibility loci in the NZM mice, Sle1 (located on chromosome 1) and 
Sle2 (located on chromosome 4) (163,164). Congenic mice expressing either the Sle1 or 
Sle2 locus have specific symptoms but none of them develop renal disease whereas 
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combining Sle1 and Sle2 resulted in glomerulonephritis and enhanced mortality (160). 
This is a strong indication of the complex multigenetic nature of lupus like disease in 
mice. Also these studies show that the genetics involved in pathogenesis of lupus is 
autosomal as well as sex chromosome linked. Additionally, Pre-B cell lines from fetal 
livers (FLs) of lupus prone (NZB x NZW)F1 mice transferred lupus-like disease to SCID 
(Severe combined immuneodeficiency) mice but it is not known if the cell lines were of 
male or female origin (165).  
It is evident that sex hormones (discussed in 1.4.2) and genetics play an important role in 
the incidence of lupus-like disease and its severity, but the relative contribution of each 
factor is not well understood. In order to address this issue we utilized a mixed BM 
chimera system to delineate the role of sex hormones and genetics/intrinsic hematopoietic 
properties of immune cells in the development of lupus like disease in (NZB x NZW)F1 
mice. The results of this study are discussed in detail in Chapter IV (Intrinsic 
autoimmune capacities of hematopoietic cells from female New Zealand hybrid 
mice; Published in Genes and Immunity, 2014). 
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CHAPTER II 
GR-1
HIGH
CD11B
+
 CELLS SUPPRESS B CELL DIFFERENTIATION AND LUPUS 
LIKE DISEASE IN LUPUS PRONE MALE MICE 
Abstract 
Objective. Systemic lupus erythematosus (SLE) develops much more readily in females 
than in males. Previous research has focused primarily on identifying mechanisms 
pertinent to the pathology in females. The aim of the current study was to delineate active 
protective mechanisms in males. We present evidence of a new male-associated 
mechanism of protection against the development of lupus-like disease in lupus-prone 
(NZB x NZW) F1 mice.  
Methods. We identified previously uncharacterized cellular and functional differences in 
myeloid cells between male and female (NZB x NZW)F1 mice, with the use of flow 
cytometry, confocal imaging, in vivo antibody-mediated depletion, and in vitro cell 
coculture assays. 
Results. A population of Gr-1
high
Ly-6G
+
CD11b
+ 
myeloid cells was found to be 
constitutively increased in male (NZB x NZW)F1 mice as compared with female mice 
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and was regulated by testosterone. The cells were located adjacent to spleen B cell 
follicles in vivo and were found to directly inhibit cytokine-induced differentiation of 
naive B cells into antibody-secreting cells in vitro. Most notably, treatment with anti–Gr-
1–depleting antibodies increased the spontaneous production of antinuclear 
autoantibodies in male (NZB x NZW)F1 mice, while a similar approach in female mice 
had no effect on disease development.  
Conclusion. Male lupus-prone (NZB x NZW)F1 mice harbor elevated levels of a 
population of myeloid cells with pronounced immunosuppressive capacities that 
specifically target B cells and the production of antibodies in vivo. We suggest that these 
cells represent a male-driven inhibitory mechanism involved in the control of B cell 
pathogenesis, delaying (or preventing) lupus-like disease development in otherwise 
genetically predisposed male (NZB x NZW)F1 mice. 
2.1 Introduction 
 Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disorder. 
The disease is characterized by elevated levels of antinuclear antibodies (ANAs) and 
cellular infiltration of various organs, including the skin, heart, and kidney(1). Like most 
systemic autoimmune diseases, SLE predominantly affects women. The female-to-male 
ratio of newly diagnosed patients reaches 9:1 between the ages of 15 years and 45 years 
(66,67). This coincides with the years when female sex hormones are the most active, and 
thus, much research has focused on elucidating the role of female sex hormones 
(particularly estrogen) in SLE. For example, it is well accepted that elevated levels of 
estrogens affect B lymphocyte selection processes by altering the threshold for negative 
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selection, thereby allowing more self-reactive B cells to survive and differentiate 
(74,166). Testosterone, on the other hand, is believed to be protective, based on mouse 
studies (70,72,73,167) and clinical data from SLE patients treated with testosterone or the 
adrenal steroid dehydroepiandrosterone (168-170). Still, the target of regulation and the 
specific mechanism of protection mediated by testosterone remain unidentified. 
In some animal models of SLE, female predominance is similarly observed. One such 
model is the (NZB X NZW) F1 hybrid mouse. Within 1 year of birth, 100% of female 
(NZB X NZW) F1 mice develop a lupus-like disease that is characterized by increased 
levels of anti-chromatin, anti-histone, and IgG anti–double-stranded DNA (anti-dsDNA) 
autoantibodies, as well as glomerulonephritis, IgG immune complex (IC) deposition 
within the kidney glomeruli followed by complement fixation, and renal disease 
(proteinuria) (69-71). In contrast, only ~30% of male (NZB x NZW)F1 mice develop 
disease within this time period. In fact, the maximum incidence in male (NZB X 
NZW)F1 mice reaches only ~65% (69). We used this model to pursue potent naturally 
occurring immunosuppressive mechanisms that actively protect genetically susceptible 
males against the development of lupus-like disease.  
In non-autoimmune individuals, self-reactive cells are kept in check by both central and 
peripheral mechanisms of tolerance. The immune regulatory network consists of 
regulatory cells of many origins. The best known component is the regulatory T cell, 
which has been extensively studied both in mouse models of lupus and in SLE patients 
(for review, see refs. (171,172). Newer members of the regulatory family include 
regulatory interleukin-10 (IL-10)–producing B cells and myeloid-derived suppressor cells 
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(MDSCs), both of which have been studied in only a few models of lupus (92,173,174). 
MDSCs represent a heterogeneous pool of immature myeloid cells that are generated in 
the bone marrow and are released under inflammatory conditions (175,176). MDSCs 
have been extensively studied under tumorigenic conditions, and antibody-mediated 
depletion of MDSCs supports tumor eradication in tumor bearing mice. Similarly, 
treatment of renal cell carcinoma patients with a receptor tyrosine kinase inhibitor 
(sunitinib) reduces the numbers of MDSCs and diminishes tumor progression (177-179). 
 We report herein the identification of a population of immunosuppressive myeloid cells 
(Gr-1
high
Ly- 6G
+
CD11b
+
) that were significantly up-regulated in a testosterone-dependent 
manner in male mice. Antibody mediated depletion of the cells in male, but not female, 
mice resulted in elevated autoantibody production and IgG IC deposition. Accordingly, 
we show that (Gr-1
high
Ly-6G
+
CD11b
+
) cells from male and female mice use different 
mechanisms of suppression in vitro and that cells from female, but not male, mice lose 
their suppressive capability with aging. We suggest that this population of myeloid-
derived cells is heterogeneous and differentially regulated in males and females, resulting 
in active protection against the development of spontaneous autoimmunity in otherwise 
genetically predisposed males. These findings offer a significant new therapeutic target 
for lupus patients. 
2.2 Materials and Methods 
2.2.1 Mice and cells 
Male and female (NZB X NZW)F1 mice (3 weeks old) were obtained from JAX Mice 
(The Jackson Laboratory) and were maintained at the Biological Resource Unit at Lerner 
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Research Institute, Cleveland Clinic. Castrated male (NZB X NZW)F1 mice (3 weeks 
old) were also obtained from JAX Mice. Slow-release pellets containing 12.5 mg or 25 
mg of 5α-dihydrotestosterone (Innovative Research of America) were inserted 
subcutaneously in the neck region of castrated mice that had been anesthetized with 
isoflurane (Terrell; Primal Critical Care). Reconstitution was considered successful when 
levels of serum testosterone had equalized to the levels in age-matched unmanipulated 
male mice. There were no statistical differences in the levels of testosterone present in 
mice receiving the 12.5-mg or the 25-mg pellets. Five weeks later, mice were killed and 
examined. All mouse experiments were approved by the local Institutional Animal Care 
and Use Committee. 
Antibody-treated mice were injected intraperitoneally every 3 days for 8 weeks with 500 
μg of anti–Gr-1 antibody (RB6-8C5 monoclonal antibody), 500 μg of rat IgG, or sterile 
filtered 1X phosphate buffered saline (PBS), each in a total volume of 200 μl. For in vitro 
studies, Gr-1
high
CD11b
+
, Gr-1
low
CD11b
+
, and B220
high
CD19
high
 cells were isolated by 
flow-based cell sorting using a FACSAria I (BD Biosciences). All sorted cells were 
confirmed to be negative for CD3 and CD11c expression. Cytospin was performed using 
Cytology Funnel disposable sample chambers (Fisher HealthCare), Shandon Cytoslides 
(Thermo Scientific), and a Cytology Cytospin 2 centrifuge (Shandon). Cells were stained 
with hematoxylin and eosin (Newcomer Supply). 
2.2.2 Flow cytometry 
Flow cytometry was performed using either a FACSCalibur or a FACSAria I instrument, 
and all analyses were done using FlowJo version 9.5.2 software (all from BD 
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Biosciences). Antibodies with the following specificities were used for all analyses: CD3, 
CD11b, CD11c, CD19, CD21, CD23, B220 (CD45R), CD49d, F4/80, Ly-6C, CD16/32, 
Gr-1 (Ly-6C/6G), IgM, and IgD (all from eBioscience). Anti– Ly-6G antibody was 
obtained from Miltenyi Biotec and anti- CXCR2 antibody from R&D Systems. 
2.2.3 Immunostaining 
For histological analyses, half kidneys were harvested and fixed in 4% 
paraformaldehyde. Glomerular structure and inflammatory cells were determined on two 
5μm sections 30μm apart after Hematoxylin/Eosin staining (Newcomer Supply). The 
number of mesangial cells/glomerulus was determined in a blinded fashion. For detection 
of IgG, IgM and complement factor 3 (C3), half kidneys were quick-frozen in OCT™ 
and 5μm sections were prepared and stained using TexasRed-conjugated anti-mouse IgG 
(Invitrogen) or anti-mouse IgM antibodies (Southern Biotech) alongside FITC-
conjugated anti-mouse C3 specific antibodies (ICL, inc.). Images were collected using an 
HC Plan Apo 20x/0.7NA objective lens on a Leica DMR upright microscope (Leica 
Microsytems) equipped with a Retiga EXi Cooled CCD Camera (QImaging). Depositions 
were quantified using ImageProJ Plus software (Media Cybernetics) and are given as 
density (green or red) per area (glomerulus). Five to eight glomeruli were measured per 
sample and data are presented as the mean ± SEM per 8 treatment group. Detection of 
Gr1-expressing cells within spleens of male and female (NZB x NZW)F1 mice were 
done using FITC-conjugated anti-Gr1 antibody (eBiosciences), APC-conjugated anti-
CD11b antibody, biotin-conjugated MOMA-1 antibody, APC or biotin-conjugated anti-
B220 antibody (eBiosciences), and Alexa Fluor 568-conjugated streptavidin on 5 μm 
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frozen sections. Confocal images were obtained using a Leica TCS-SP-AOBS Spectral 
Laser Scanning Confocal Microscope (Leica Microsystems) and analyzed using Leica 
Confocal Software (Leica Microsystems). 
2.2.4 Elution of antibodies from kidneys 
Total antibodies were eluted from frozen kidneys. Briefly, kidneys were thawed, cut into 
smaller pieces (<1 mm diameter) and added Urea-Glycine buffer (0.5M Urea, 0.15M 
glycine, pH 2.8) at a 1:5 weight/volume ratio. Then samples were sonicated 5 cycles of 
30 sec./30 sec. rest, and left ON at 4°C. Supernatants were harvested after centrifugation 
and applied to Amicon Ultra 3K centrifugal filters (EMD Millipore, MA). All kidneys 
were weighed before elution and the final elution volume was determined. Eluted 
antibodies were diluted 1:500 and tested for anti-dsDNA reactivity by ELISA as 
described below. The amount of antibodies per kidney is given as U/μg tissue and was 
calculated as: [Ab, U/μl] / [μg kidney/μl elution volume]. 
2.2.4 In vitro B cell differentiation 
Flow-sorted CD19
high
 B cells (2 x 10
5
/well) were plated with variable numbers of flow 
sorted Gr1highCD11b+ or Gr1lowCD11b+ cells in the presence or absence of 
recombinant IFNα (500 units/ml, PBL InterferonSource) and recombinant CD40L 
(10μg/ml, EBiosciences) in complete media (RPMI1640 w/ 10% FBS, 1% non-essential 
amino acids, 1% pen/strep, 1mM Na-Pyruvate). After 72 hrs, cells were harvested and 
25.000 cells/well were transferred onto ELISPOT plates (Millipore) pre-coated with anti-
Ig antibody (Southern Biotech). Remaining cells were stained for Gr1 and B220-
expressing cells and analyzed for the relative survival of each cell subset by flow 
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cytometry. After additional 20hrs, cells were removed and plates were developed using 
HRP-conjugated anti-IgG and anti-IgM specific secondary antibodies (KPL and Southern 
Biotech) and AEC Substrate set (BD Biosciences). The numbers of IgM or IgG-secreting 
cells were detected on an ELISPOT reader (CTL Immunospot) and are given as number 
of spots per 105 B cells. Where noted, sorted Gr1highCD11b+ cells were pretreated with 
20mM N-Acetyl-L-Cysteine (NAC) a ROS inhibitor (Sigma, MO) or 10μM Nω-L-
Arginine methyl ester hydrochloride (L-NAME) a NOS inhibitor (Sigma, MO) for 30 
min. at 37°C, before being added to CD19
+
 B cells. 
2.2.5 Anti-nuclear Autoantibody ELISA 
Serum obtained from anti-Gr1 antibody and control-treated animals, before, during and 
after treatment ended, was diluted 1:300 in serum diluent (sterile filtered 0.5% bovine γ-
globulin, 5% gelatin, 0.05mM Tween in 1x PBS) and analyzed for levels of anti-
chromatin, anti-histone and anti-dsDNA IgG autoantibodies. Briefly, microtiter plates 
(Immulon 2HD) were coated with purified chromatin or total histones over night at 4°C, 
blocked in 5% gelatin/PBS for ≥2hrs, and incubated with samples for 2 hrs. Secondary 
HRP-conjugated anti-mouse IgG antibodies (Invitrogen) were added for 1.5 hrs and 
plates were developed using 10mg/ml 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid)(ABTS) in McllWain’s buffer (0.09 M Na2HPO4, 0.06 M citric acid, pH 4.6). Anti-
dsDNA IgG IgG levels were determined using the manufacturer’s protocol (Alpha 
Diagnostic International Inc., TX). 
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2.2.6 Cytokine ELISA 
Serum cytokine levels were measured using the manufacturer’s protocols (BAFF and IL-
10 (EBiosciences), IL-6 (R&D Systems)). Briefly, serum samples were diluted 1:3 
(BAFF), 1:10 (IL-6), or 1:4 (IL-10) and added to pre-coated Immulon 2-HB microtitre 
plates (Thermo Scientific, MA). Concentrations of serum cytokines were calculated 
based on OD values obtained from the supplied recombinant cytokine standard. All 
calculations were done using GraphPad Prism software (ver. 5.02). 
2.2.7 Statistical analyses 
The statistical significance between the means of two groups was determined using 
Student’s t-test or the non-parametric Mann-Whitney test. 
2.3. Results 
2.3.1. NZB x NZW)F1 male mice harbor elevated levels of Gr1
high
CD11b
+
 cells as 
compared with age-matched (NZB x NZW)F1 female mice 
To identify potential immune mechanisms acting differentially in males and females prior 
to puberty, we analyzed the cellular immune compartment present in spleens of male and 
female lupus-prone (NZB X NZW)F1 mice at 4 weeks of age. Contrary to our 
expectations, we found no significant differences between the sexes within 
subpopulations of T cells, B cells, and dendritic cells (Figure 2.1 A). Rather, we found 
consistently elevated levels of two myeloid cell populations characterized by the co-
expression of CD11b (Mac-1) and Gr1 (Ly6G/Ly6C): Gr1
high
CD11b
+
 and Gr1
low
CD11b
+
 
cells (Figure 2.1 A-B, p < 0.01). Further analyses showed that splenic Gr1
high
CD11b
+
 
cells were significantly elevated in males as compared with females in percentages (p < 
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0.05-0.001), as well as in total numbers (p < 0.05-0.01), throughout the first 6 months of 
life (Figure 2.1 C, left panel). Total numbers of the corresponding population of splenic 
Gr1
low
CD11b
+
 cells were also significantly elevated in 4 wk old male (NZB x NZW)F1 
mice as compared with females (p < 0.01), but not in older mice (Figure 2.1 C, right 
panel). To determine if the elevated levels of Gr1
high
CD11b
+
 cells in male mice were due 
to regulation by male sex hormone, we analyzed levels of cells in castrated and hormone-
reconstituted (NZB x NZW)F1 mice. Both numbers and percentages of splenic 
Gr1
high
CD11b
+
 cells significantly decreased in castrated male, but not ovariectomized 
female, mice as compared with unmanipulated littermates (p < 0.001; Figure 2.1 D). The 
effect was specific to the effect of testosterone, as reconstitution of castrated male mice 
with 5α-dihydrotestosterone, which cannot be converted to estradiol, replenished levels 
of Gr1
high
CD11b
+
 cells. (p < 0.0001; Figure 2.1 D). 
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Figure 2.1 Elevated levels of splenic Gr1
high
CD11b
+
 cells in male as compared with 
female (NZB x NZW)F1 mice. (A) Percentages of T cells, B cells, DCs and monocytes 
in 4 wk old male (M) and female (F) (NZB x NZW)F1 mice. Each data point represents 
an individual mouse. Tr: Transitional B cells, FM: Follicular Mature B cells, MZ: 
Marginal Zone B cells, PC: Plasma Cells, cDCs: conventional DCs (CD11c
+
B220
-
), 
pDCs: plasmacytoid dendritic cells (CD11c
+
B220
+
). (B) Representative contour plots 
showing the levels of Gr1
high
CD11b
+ 
and Gr1
low
CD11b
+
 cells in 4 wk old male and 
female (NZB x NZW)F1 mice. (C) Absolute numbers and percentages of Gr1
high
CD11b
+
 
cells (left panel) and Gr1
low
CD11b
+
 cells (right panel) in male (black diamonds, black 
bars) and female (gray triangles, gray bars) in 4, 9 and 26 week old (NZB x NZW)F1 
mice. Data are shown as the average ± SEM of cells in ≥5 individual mice obtained in >5 
independent analyses. (D) Splenic Gr1
high
CD11b
+
 cells are regulated by testosterone. 
Percentage of cells was measured 5 weeks post-surgery in unmanipulated (black 
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diamonds), castrated (white diamonds) and castrated + 5α-dihydro-testosterone treated 
(gray diamonds) mice. * p < 0.05; ** p < 0.01; *** p < 0.001. 
2.3.2. Gr1
+
CD11b
+
 cells in young (NZB x NZW)F1 mice locate to the perifollicular 
regions of the spleen and share surface markers with both neutrophils and MDSCs 
Gr1-expressing cells have recently been found to locate to the perifollicular region in 
healthy humans and non-autoimmune mice (113). Confocal imaging of immunostained 4 
wk old (NZB x NZW)F1 mouse spleen sections confirmed the localization of 
Gr1
+
CD11b
+
 cells adjacent to B lymphocytes (Figure 2.2 A). The pattern of localization 
was not significantly different between males and females, although we observed slightly 
more Gr1
+
 cells within the marginal zone areas of males than of females (Figure 2.2 A a-
c, arrows). We further characterized the cells with regard to cellular morphology and cell 
surface marker expression: Gr1
high
CD11b
+
 cells had a phenotype of 
Ly6G
+
Ly6C
low
CD49d
-
F4/80
-
CD124
-
 and displayed a neutrophilic nuclear morphology, 
while Gr1lowCD11b+ cells were Ly6G
-
Ly6C
high
CD49d
+
F4/80
+
CD124
low
 and had a 
monocytic appearance (Figure 2.2 B-C). These patterns are shared with, but not exclusive 
to, monocytic and neutrophilic MDSCs (121,175,180,181). In addition, we found that 15-
25% of splenic Gr1
high
CD11b
+
 cells from 4 wk old (NZB x NZW)F1 male and female 
mice coexpressed CXCR2, the prototypic surface chemokine receptor of mature 
neutrophils (Figure 2.2 C, bottom panel). CXCR2 was not expressed by Gr1
low
CD11b
+
 
cells. 
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Figure 2.2 Gr1
high
CD11b
+
 cells display phenotypic characteristics of granulocytic 
myeloid-derived suppressor cells. (A) Confocal microscopy analysis of the intra-splenic 
localization of Gr1-expressing cells in 4 week old female (a,b) or male (c) (NZB x 
NZW)F1 mice. Stippled lines (a and c) outlines B cell follicle and arrows (a and c) point 
to Gr1-expressing cells within the peri-follicular region. B: B cell follicle; T: T cell zone. 
Pictures were taken at 40x magnification and are representative of 5 female and 4 male 
28 samples. (B) Cytospin analysis of Gr1
low
CD11b
+
 and Gr1
high
CD11b
+
 cells. Nuclear 
morphology was determined after H&E staining. (C) Flow cytometry analysis of cell 
surface markers on Gr1
low
CD11b
+
 and Gr1
high
CD11b
+
 cells from 4 wk old (NZB x 
NZW)F1 mice. Cells were costained for Ly6C, Ly6G, CD49d, F4/80, CD124 (IL-4rα) 
and CXCR2. Level of expression of each marker is given in a histogram (blue line: male; 
red line: female) after gating on each subset individually. Data represent 3 or more 
independent analyses. 
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2.3.3. Gr1-expressing cells suppress autoantibody production, IL-10 production, and 
lupus-like disease in male, but not female (NZB x NZW)F1 mice in vivo. 
Given the well-known differential development of lupus-like disease in (NZB x NZW)F1 
males and females, we investigated if the uneven levels of Gr1
high
CD11b
+
 and 
Gr1
low
CD11b
+
 cells in male and female mice could be involved in the control of 
spontaneous lupus-like disease. We treated adult 11-15 wk old male and female (NZB x 
NZW)F1 mice with depleting anti-Gr1 antibody every three days for 8 weeks 
determining disease activity by means of serum anti-nuclear autoantibody levels and 
proteinuria. Functional depletion was verified in PBMC fractions after 4 and 6 weeks of 
depletion; levels of circulating Gr1
+
CD11b
+
 cells were constitutively reduced among 
total PBMCs from both males (from 28% to 9.2%) and females (from 15% to 9.5%). 
Continuous anti-Gr1 antibody treatment of male (NZB x NZW)F1 mice resulted in 
significantly elevated levels of serum anti-dsDNA IgG during and after ended treatment 
(p < 0.05)(Figure 2.3 A, right panel), as well as transiently elevated anti-histone IgG 
levels (Figure 3A, left panel) and IgG antichromatin (data not shown). In contrast, anti-
Gr1 antibody treatment of female (NZB x NZW)F1 mice had little or no effect on the 
level of anti-nuclear IgG autoantibodies (Figure 2.3 B).  
Other serological abnormalities previously identified in female (NZB x NZW)F1 mice 
include elevated BAFF, IL-6 and IL-10 (109,182-184). Quantification of these factors in 
anti-Gr1 antibody treated mice, showed significantly elevated levels of serum IL-10 in 
response to the depletion of Gr1+ cells in both male and female mice (Figure 2.3 C-D), 
but no differences in serum levels of either BAFF or IL-6 (data not shown).  
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Figure 2.3 In vivo depletion of Gr1-expressing cells increases autoantibody 
production and IL-10 secretion in male (NZB x NZW)F1 mice. Male (A) or female 
(B) (NZB x NZW)F1 mice were treated with 500μg anti-Gr1 antibody (black squares), 
rat IgG antibody (gray triangles) or PBS (white triangles) every 3 days for 8 weeks (gray 
shaded area) starting at 11-15 weeks of age. Serum samples were obtained before, during 
and after treatment and levels of anti-histone IgG (left side panels) and anti-dsDNA IgG 
(right side panels) were determined by ELISA. The p-value for anti-Gr1 treated versus rat 
IgG-treated mice is given in the upper right corner of each graph. Statistical comparison 
of autoantibody levels at individual time points is given by asterisks (*). (C-D) Serum IL-
10 levels were measured in male (C) and female (D) (NZB x NZW)F1 after ended 
treatment at 19-23 weeks of age. n = 8 (anti-Gr1 IgG treated males, females), n = 7 and 3 
(rat IgG treated males, females, respectively), n = 4 and 2 (PBS-treated males, females, 
respectively). * p< 0.05; ** p < 0.01; *** p < 0.001. 
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2.3.4. The development of glomerulonephritis is unaffected by anti-Gr1 Ab 
treatment  
Lupus-like disease in (NZB x NZW)F1 mice is also characterized by glomerulonephritis, 
glomerular IgG-IC deposition, and complement fixation. Anti-Gr1 antibody treated male 
(NZB x NZW)F1 mice displayed no significant differences in glomerular size and 
cellularity, or tubulointerstitial inflammation (Figure 2.4 A-B).  
 
Figure 2.4 The development of glomerulonephritis is unaffected by anti-Gr1 Ab 
treatment. (A) Representative pictures of hematoxylin/eosin stained kidney sections 
from male (NZB x NZW)F1 mice treated with PBS (upper left), rat IgG control Ab 
(upper right), or rat anti-Gr1 Ab (lower left) 8 weeks post treatment. Arrows point to 
glomeruli. (B) The area per glomerulus was calculated for PBS-treated (n = 4 mice), rat 
IgG-treated (n = 5 mice), and anti-Gr1 Ab-treated (n = 6 mice). Each dot represents the 
average of 3-5 glomeruli per mouse. 
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2.3.5. IgG-IC deposition is increased in anti-Gr1 treated male mice 
IgG-IC deposition was significantly elevated within the kidney glomeruli of anti-Gr1 
antibody treated males, reaching levels equivalent to female age-matched control mice 
(Figure 2.5 A-B). This pattern was specific to IgG-IC, as no increase was observed in the 
levels of IgM deposition (Figure 2.5 B). Further analysis of the specificity of deposited 
autoantibodies after elution from a subset of the kidneys revealed elevated levels of anti-
dsDNA IgG autoantibodies in anti-Gr1 antibody treated males (Figure 2.5 C). 
Complement fixation, as measured by C3 immunostaining, was not increased in the anti-
Gr1 antibody treated group (Figure 2.5 B) and renal failure was not observed in any of 
the mice (dipstick proteinuria readings: PBS treated = 1.5 ± 0.0 (n = 4); rat IgG Ab-
treated = 1.3 ± 0.7 (n = 5); anti-Gr1 Ab treated = 1.6 ± 0.3 (n = 7)). Thus, depletion of 
Gr1-expressing cells at 11-15 wks of age resulted in elevated levels of serum anti-
dsDNA, anti-histone and anti-chromatin IgG, elevated serum IL-10, as well as increased 
anti-dsDNA IgG deposition in male mice. In female mice, depletion of Gr1-expressing 
cells resulted in equally elevated levels of serum IL-10, but no increase in anti-nuclear 
autoantibody production. 
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Figure 2.5 IgG-IC deposition is increased in anti-Gr1 treated male mice. (A) 
Representative immunofluorescence staining of IgG (red) and C3 (green) deposition in 
anti-Gr1 Ab, rat IgG, or PBS treated males, as well as age-matched untreated control 
females. Pictures shown are representative of 4-6 mice per group. (B) Quantification of 
the level of IgG, IgM and C3 staining per glomerulus as shown in (A). Quantification 
data represent the average level of staining in individual mice ± standard error of the 
mean (4-6 mice per group and 5-12 glomeruli per mouse were analyzed). (C) Levels of 
dsDNA reactive IgG’s were measured by ELISA after elution of total antibodies from a 
subset of frozen kidneys.* p < 0.05.  
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2.3.6. Gr-1
high
CD11b
+
 cells directly suppress B cell differentiation in vitro 
Based on the intra-splenic localization of Gr1-expressing cells and the effect on anti-
nuclear autoantibody production after Gr1
+
-cell depletion in male (NZB x NZW)F1 mice, 
we hypothesized that Gr1
high
CD11b
+
 cells were involved in the control of B cell 
activation, differentiation and/or effector mechanisms. We therefore tested if 
Gr1
high
CD11b
+
 or Gr1
low
CD11b
+
 cells isolated from male and female 4 wk old (NZB x 
NZW)F1 mice could directly suppress B cell differentiation in vitro in a T cell-free 
system. Upon coculture with increasing numbers of Gr1
high
CD11b
+
 cells, but not 
Gr1
low
CD11b
+
 cells, cytokine-driven B cell differentiation was significantly inhibited in a 
dose dependent manner (Figure 2.6 A-B). The suppressive effect was equally present 
using Gr1
high
CD11b
+
 cells from 4 wk old male or female mice. 
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Figure 2.6 Gr1
high
CD11b
+
 cells, but not Gr1
low
CD11b
+
 cells, suppress B cell 
differentiation in vitro. B cells (CD19
high
), Gr1
low
CD11b
+
 and Gr1
high
CD11b
+
 cells were 
isolated from spleens of 4 wk old male (A) or female (B) mice and co-cultured for 72 hrs 
at variable ratios (B cell to Gr1-cell ratios: 4:1, 8:1 or 16:1) in the presence of B cell 
differentiation-inducing cytokines (recombinant IFNα and CD40L). Total numbers of 
IgM- and/or IgG-secreting plasma cells were detected by ELISPOT and are given as the 
number of spots per 10
5
 B cells. Each bar represents the mean ± SEM. Data represent 5-8 
independent assays. * p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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2.3.7. Gr-1
high
CD11b
+
 cells from female, but not male, (NZB x NZW)F1 mice 
suppress B cell differentiation via ROS/nitric oxide (NO) 
Gr1-expressing cells have been reported to suppress adaptive immune responses via 
numerous suppressor mechanisms including the production of reactive oxygen species 
(ROS) and nitric oxide (NO)(reviewed in (175)). Pretreatment of Gr1
high
CD11b
+
 cells 
from female (NZB x NZW)F1 mice with inhibitors of either ROS or NO synthase (NOS) 
completely abrogated the suppressive effect of the cells (Figure 2.7 , right-side panel). In 
contrast, similar treatment of male-derived Gr1
high
CD11b
+
 cells had no effect on the 
suppressive capacity of the cells (Figure 2.7, left-side panel). Thus, although male and 
female Gr1
high
CD11b
+
 cells from 4 week old prepubertal (NZB x NZW)F1 mice suppress 
B cell differentiation equally well, the cells appear to operate through different molecular 
mechanisms. 
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Figure 2.7 Gr-1
high
CD11b
+
 cells from female, but not male, (NZB x NZW)F1 mice 
suppress B cell differentiation via ROS/nitric oxide (NO). Gr1
high
CD11b
+
 cells were 
isolated from spleens of 4 wk old male or female mice and were pretreated with L-
NAME (NOS inhibitor) or NAC (ROS inhibitor) before added to B cells and co-cultured 
with B cells as described earlier. Gr1
high
CD11b
+ 
cells each bar represents the mean ± 
SEM. Data represent 5-8 independent assays. * p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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2.3.8 Male Gr1
high
CD11b
+
 cells remain suppressive in older mice 
The in vivo effect of Gr1
+
-cell depletion, as described above, was measured in older mice. 
We therefore analyzed the effect of Gr1
high
CD11b
+
 and Gr1
low
CD11b
+
 cells isolated from 
14-16 wk old mice. Interestingly, male Gr1
high
CD11b
+
 cells from 14-16 wk old mice 
remained suppressive at the 4:1 ratio [B cells : Gr1
high
CD11b
+
 cells] (p < 0.01), while 
female Gr1
high
CD11b
+
 cells lost their suppressive capacity (p = 0.27) (Figure 2.8 A-B). 
This was not due to a defect in the B cells from older (NZB x NZW)F1 females, as these 
cells could be suppressed using Gr1
high
CD11b
+
 cells isolated from either 4 wk old 
females or 14 wk old males (Figure 2.8 B). 
 
 
 
 
Figure 2.8 Only male Gr1
high
CD11b
+
 cells remain suppressive in older mice. 
Gr1
high
CD11b
+
 cells were flow sorted cells from 14-16 wk old male (A) and female (B) 
(NZB x NZW)F1 mice and added to B cell cultures in the presence of CD40L and IFNα 
(n = 7-8). Numbers of IgM or IgG producing plasma cells were enumerated by ELISPOT 
after 4 days. In (B) B cells isolated from 14 wk old female (NZB x NZW)F1 mice were 
exposed to Gr1
high
CD11b
+
 cells from either 14 wk old females at 4:1, 8:1 or 16:1 ratios (n 
= 7), or from 4 wk old female or 14 wk old male (NZB x NZW)F1 mice at a 4:1 ratio 
(each n = 2). * p < 0.05; ** p < 0.01; *** p < 0.001. ns: not statistically significant. 
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2.3.9 Gr1
low
CD11b
+
 cells from older male and female (NZB x NZW)F1 mice 
stimulate B cell differentiation in vitro.  
As female (NZB x NZW)F1 mice age, the ratio of Gr1
high
CD11b
+
 to Gr1
low
CD11b
+
 cells 
change in favor of the monocytic Gr1
low
CD11b
+ 
population (see Figure 2.1). At the same 
time, anti-Gr1 antibody treatment failed to affect anti-nuclear autoantibody production in 
females in vivo (see Figure 2.3). We speculated that Gr1
low
CD11b
+
 cells in adult (NZB x 
NZW)F1 mice acquired a stimulatory phenotype, as previously described in both SLE 
patients and a pristane-induced model of lupus (113,185,186). In agreement, 
Gr1
low
CD11b
+
 cells from both male and female 14-16 wk old (NZB x NZW)F1 mice 
exhibited a stimulatory phenotype promoting B cell differentiation in our T-cell free in 
vitro cell system (p < 0.05) (Fig. 9 A-B). 
 
 
 
 
 
Figure 2.9 Gr1
low
CD11b
+
 cells from older male and female (NZB x NZW)F1 mice 
stimulate B cell differentiation in vitro. In older mice, Gr1
low
CD11b
+
 cells become 
immunostimulatory. Gr1
low
CD11b
+
 cells were flow sorted cells from 14-16 wk old male 
(A) and female (B) (NZB x NZW)F1 mice and added to B cell cultures in the presence of 
CD40L and IFNα (n = 7-8). Numbers of IgM or IgG producing plasma cells were 
A B 
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enumerated by ELISPOT after 4 days. * p < 0.05; ** p < 0.01; *** p < 0.001. ns: not 
statistically significant. 
2.4 Discussion 
SLE predominantly affects females. Over the past many years, it has been known that the 
male sex hormone, testosterone, exerts suppressive functions on disease development and 
severity (70,72,73,167-170). However, the mechanism(s) by which testosterone may 
influence the immune system of lupus-prone individuals in a protective manner is not 
well understood. In this study we investigated a mechanism of immunosuppression 
mediated by a population of myeloid cells (Gr1
high
Ly6G
+
CD11b
+
), found to be present at 
higher levels in male than female lupus-prone (NZB x NZW)F1 mice. Manipulation of 
testosterone levels through pre-pubertal castration, but not estrogen levels, significantly 
influenced the levels of Gr1
high
CD11b
+
 cells in vivo, suggesting that this 
immunosuppressive mechanism is regulated by male sex hormone. We propose that 
regulation of immunosuppressive Gr1
high
CD11b
+
 cells represent one of the missing links 
in testosterone-mediated protection from SLE and lupus-like disease.  
It is likely that Gr1
high
CD11b
+
 cells are a heterogeneous population consisting of one or 
more of several identified cell subsets, such as neutrophils, dendritic cell precursors and 
immature monocytes (175). All of these cell subsets are well-documented 
immunostimulatory players in the pathogenesis of established lupus as compared with 
healthy individuals without an autoimmune disease (101,187,188), but to our knowledge, 
no study has analyzed the numbers and function of the cells in genetically predisposed 
but undiagnosed male versus female individuals. Our data shows that Gr1-expressing 
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cells are immunosuppressive in young lupus-prone male and female mice, but that the 
cells remain immunosuppressive in older male mice only. Consistent with this finding, 
depletion of Gr-1
high
CD11b
+
 cells in male (NZB x NZW)F1 mice resulted in increased 
serum ANA levels, while depletion in female mice had no significant effect. Despite 
increased deposition of IgG anti-dsDNA antibodies in the kidneys of male (NZB x 
NZW)F1 mice, they did  not develop renal damage or proteinuria. The dissociation of 
antibody levels, IgG IC deposition, and renal disease is a well-known phenomenon that 
has been observed in many mouse models of SLE (189-191), suggesting that either 1) 
antibodies with alternate, as-yet-unknown specificities are involved in the pathogenesis 
of the disease or 2) additional, potentially female-intrinsic factors are required to confer 
susceptibility to end-organ—in this case, kidney— damage. 
Gr1-expressing cells can suppress immune functions by numerous different mechanisms 
including ROS, NO, IL-10, TGFβ and arginase-1 (175). We do not believe IL-10 and 
TGFβ are involved in directly suppressing B cell differentiation, as targeting IL-10 or 
TGFβ by neutralizing antibodies in our in vitro B cell stimulation assay failed to reverse 
the suppressor capacity of male and female Gr1
high
CD11b
+
 cells from male and female 
mice (Khan and Jorgensen, unpublished observation). In fact, removal of Gr1-expressing 
cells in vivo resulted in significantly elevated levels of IL-10, confirming a potential 
disease-promoting effect of this cytokine, as previously suggested in both human and 
animal studies (137,183). Ongoing studies aim at identifying the cellular source of this 
IL-10 and determining whether IL-10 is indeed involved in driving autoantibody 
production in anti-Gr1 antibody-depleted male (NZB x NZW)F1 mice.  
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In vitro, we found ROS/NO production to be critical for suppression of B cell  
differentiation by Gr1
high
CD11b
+
 from female (NZB x NZW)F1 mice. ROS and NO are  
most often associated with pro-inflammatory conditions, and levels of ROS are in fact 
elevated in SLE patients, especially within neutrophils, and correlated with SLEDAI 
scores (192,193). Similarly, elevated ROS levels have been documented in BALB/c mice 
with pristane-induced lupus and in the MRL
lpr/lpr 
mouse model of lupus (194,195). 
Furthermore, inhibition of inducible NOS in female (NZB x NZW)F1 mice with 
proteinuria suppresses renal disease via reductions in ROS levels (196). It remains to be 
seen whether excessive ROS/NO production by Gr-1–expressing cells from young female 
mice is involved in the disease progression in older mice. As shown in our in vitro B cell 
differentiation assay, Gr-1
high
CD11b
+
 cells from 4-week-old male (NZB x NZW)F1 mice 
did not use ROS/NO as their mechanism of suppression. It is therefore possible that the 
heterogeneous population of Gr-1
high
CD11b
+
 cells is composed of different cell subsets in 
male mice as compared with female mice. Identification of the specific subset of Gr-
1
high
CD11b
+
 cells with ROS/NO independent suppressor capacities in male (NZB x 
NZW)F1 mice will be of utmost interest in our search for new diagnostic tools and 
treatment strategies. These data obtained in mice lead us to suggest those differential 
levels of Gr-1
high
CD11b
+
 cells, as well as the potential usage of different suppressor 
mechanisms—if ultimately detected in humans as well—might be actively involved in 
delaying or preventing SLE in otherwise genetically predisposed male mice. 
 
In addition to the Gr1
high
CD11b
+
 cells, a population of Gr1
low
Ly6G-CD11b
+
 cells is also 
present at higher levels in males before puberty (at 4 weeks of age), but increases in 
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females as they age. This population of cells concurrently acquires a stimulatory 
phenotype promoting cytokine-dependent B cell differentiation in vitro. A positive 
correlation between the numbers of Gr1
low
CD11b
+
 cells and autoantibody production has 
also previously been observed in a model of pristine-induced lupus (186), and a similar 
population of cells was recently found to promote T-cell independent B cell 
differentiation in humans (113). Whether the age-dependent accumulation of 
Gr1
low
CD11b
+ 
cells in female (NZB x NZW)F1 mice is a result of disease progression 
and underlying inflammation remains to be determined. 
Based on our findings reported here, we suggest that the balance between Gr1
high
CD11b
+
 
and Gr1
low
CD11b
+
 cells, as well as the composition of cells within the Gr1
high
CD11b
+
 
cell population, may be instrumental in protecting genetically predisposed males from 
lupus-like disease development. Both male and female (NZB x NZW)F1 mice display 2-
3 times more Gr1
high
CD11b
+
 cells than Gr1
low
CD11b
+
 cells before puberty, and hence 
maintain an immunoinhibitory milieu. The ratio remains in favor of Gr1
high
CD11b
+ 
cells 
in males up until at least 26 wks of age, however already around 9 weeks of age, female 
(NZB x NZW)F1 mice harbored higher numbers of Gr1
low
CD11b
+
 cells than 
Gr1
high
CD11b
+
 cells. Thus, as the females enter puberty the balance shifts towards the 
more immunostimulatory population. We therefore suggest that testosterone mediates its 
suppressive effect via the maintenance of a population of immunoinhibitory 
Gr1
high
CD11b
+
 cells. Our studies further suggest that this population is specifically 
involved in limiting the production of pathogenic IL-10 in vivo. Studies addressing ways 
to induce higher numbers of suppressive, ROS/NO-independent, Gr1
high
CD11b
+
 cells in 
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females is therefore of outmost interest as we aim to identify ways to delay or prevent B 
cell activation, differentiation and ultimately lupus-like disease. 
Finally, it is worth mentioning, that although the majority of male mice harbor elevated 
numbers of Gr1
high
Ly6G
+
CD11b
+
 cells as compared with female mice, a subset of mice 
(~25%) demonstrated less of an increase. This proportion correlates with the number of 
male (NZB x NZW)F1 mice that will develop a lupus-like disease within the first year of 
life (30-40%). Thus, measurements of prepubertal levels of Gr1
high
CD11b
+
 cells could 
potentially be used as a diagnostic tool, while manipulation of Gr1-expressing cell 
populations may represent a new target for immune intervention. 
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CHAPTER III 
 
GR1
+
 CELLS SUPPRESS T DEPENDENT ANTIBODY RESPONSES IN (NZB x 
NZW)F1 MALE MICE THROUGH INHIBITION OF T FOLLICULAR HELPER 
CELLS AND GERMINAL CENTER FORMATION 
 
Abstract 
Systemic lupus erythematosus is an autoimmune disease characterized by elevated 
production of autoreactive Abs. The disease has a much higher prevalence in women than 
in men. Although testosterone has been shown to be protective in the disease, and 
estrogens exacerbating, the discrepancy in prevalence between men and women is still 
not well understood and the mechanism behind it is unknown. We have recently 
described that male (New Zealand black [NZB] x New Zealand white [NZW])F1 mice 
have higher levels of Gr1
+
CD11b
+
 cells, and that these cells suppress autoantibody 
production in vivo. In this article, we extend our findings to show that similarly to 
humans, female lupus-prone (NZB x NZW)F1 mice also respond with stronger Ab 
responses to thymus dependent Ag immunization than male littermates. Furthermore, the 
presence or absence of Gr1-expressing cells not only control Ag-specific Ab responses in 
male, but not female, (NZB x NZW)F1 mice, but also significantly alter the activation 
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and differentiation of CD4+ T cells in vitro and in vivo. In particular, we found that Gr1+ 
cells from male (NZB x NZW)F1 mice suppress the differentiation and effector function 
of CXCR5
+
PD-1
+
 T follicular helper cells, thereby controlling germinal center formation 
and plasma cell differentiation. This new finding strongly supports efforts to develop new 
drugs that target myeloid cell subsets in a number of T and B cell–mediated diseases with 
a female predominance. 
3.1 Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the 
production of autoreactive Abs resulting in a variety of symptoms including fatigue, skin 
rashes, arthritis, and nephropathy leading to renal failure (1,197,198). One mouse model 
used to study lupus is the (New Zealand black [NZB] x New Zealand white [NZW]) F1 
strain. Lupus-like disease in the (NZB x NZW)F1 mice is characterized by hyperactive B 
cells, abnormal autoantibody production, and ectopic germinal center (GC) formation, 
and has been shown to depend on CD4
+
T cell help (127,128,199,200). Upon activation, 
CD4
+
 T cells can differentiate into several effector cell subsets characterized by their 
unique production of effector cytokines, that is, Th1 (IFN-γ), Th2 (IL-4, IL-5), Th9 (IL-
9), Th17 (IL-17), or T follicular helper cells (TFH; IL-21). Although all of these subsets 
can influence B cell activation and/or differentiation, IL-21–producing TFH cells are 
critically required for GC formation and plasma cell (PC) differentiation (154,201,202). 
Consistent with lupus being a B cell–dependent, autoantibody mediated disease; TFH cells 
and IL-21 have been found to be involved in at least some aspects of lupus-like disease 
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development in several mouse models (203-205). Importantly, studies have also 
demonstrated dysregulated TFH cells in SLE patients (153,206,207). 
Like many other autoimmune diseases, SLE disproportionately affects women more than 
men (64). Hormonal therapy has been successfully applied in severe cases of SLE, 
suggesting that sex hormones play a major role in determining disease development in 
genetically predisposed individuals (168-170). Likewise, female (NZB x NZW)F1 mice 
develop lupus-like disease with a much higher incidence than male (NZB x NZW)F1 
mice (70,71). The female predominance observed in the (NZB x NZW)F1 mouse model 
is known to be controlled in part by sex hormones (72,73,81,208,209). Interestingly, it 
has been suggested that sex hormones also partake in defining the magnitude of immune 
activation during infections and after immunizations in healthy individuals ((209) and 
reviewed in Ref. (210)). 
Our laboratory recently described the presence of a population of testosterone-regulated 
immunosuppressive Gr1
+
CD11b
+
 cells in male (NZB x NZW)F1 mice (211). 
Particularly, we found that depletion of Gr1-expressing cells augmented spontaneous 
autoantibody production in male (NZB x NZW)F1 mice, whereas a similar strategy had 
no effect on autoantibody production in female mice. In this study, we tested whether the 
immune-suppressive function of Gr1
+
CD11b
+
 cells observed in male lupus-prone (NZB x 
NZW)F1 mice also affected immune activation in response to exogenous Ag. As 
expected, male (NZB x NZW)F1 mice responded less vigorously to immunization with a 
T-dependent Ag, whereas depletion of Gr1-expressing cells augmented the Ag-dependent 
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Ab response in males, but not in females. In correlation, numbers of both TFH cells and 
GC B cells were elevated after Gr1
+
 cell depletion. Thus, manipulation of analogous 
human cells might offer a new potential target for improving vaccination efficacy in 
individuals with low Ab responses, as well as repressing Ab production in systemic 
autoimmunity. 
3.2 Materials and Methods 
3.2.1 Mice and Immunizations 
Three-week-old male and female (NZB x NZW)F1 mice were obtained from The Jackson 
Laboratories and kept at the Biological Resource Unit at Lerner Research Institute, 
Cleveland Clinic. All mouse experiments were approved by the local Institutional Animal 
Care and Use Committee. Mice were bled at 8 wk of age, and PBMCs were analyzed for 
the presence of Gr1
+
CD11b
+
 cells by flow cytometry, allowing for stratification of the 
mice into equal groups based on their basal levels of Gr1
+
CD11b
+
 cells. At 9 wk of age, 
mice were injected i.p. with 20 μg (4-hydroxy-3-nitrophenylacetyl)27 conjugated chicken 
γ-globulin (NP27-CGG) or NP27-FICOLL [both from Biosearch Technologies, Petaluma, 
CA]), in a ratio of 1:1 with CFA (Sigma-Aldrich, St. Louis, MO), or with 1x PBS. Each 
injection was done in a total volume of 200 μl. Ab-treated mice were additionally injected 
i.p. every 3 d starting on day 21 with either 500 μg rat anti-mouse Gr1 (clone RB6-8C5, a 
kind gift from Dr. Pearlman, Case Western Reserve University, Cleveland, OH), 500 μg 
control rat IgG, or sterile-filtered PBS, each in a total volume of 200 μl as previously 
described (211). This treatment strategy was based on data showing that Gr1-expressing 
cells were fully depleted from BM, spleen, and blood for 2 d, and only began to reappear 
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on day 3 after injection with anti-Gr1 Ab (data not shown). Ab treatment was continued 
for up to 28 d as stated in the text. Mice were bled for serum by tail-vein bleeding on day 
-1, day 7, and every 7 d thereafter as applicable. 
3.2.2 Flow cytometry 
Flow cytometry was performed using a FACSCalibur (BD Biosciences, San Jose, CA), 
and all analyses were done using FlowJo Version 9.3. Abs with the following 
specificities were used for all analyses: FITC-conjugated anti- CD3 (clone 145-2C11), 
PE- or allophycocyanin-conjugated anti-CD4 (clone L3T4), PerCP-conjugated anti-CD8 
(clone 53-6.7), PE- or allophycocyanin-conjugated anti-CD11b (clone M1/70), PE-
conjugated anti-CD38 (clone 90), FITC- or PerCP-conjugated anti-B220 (CD45R; clone 
RA3-6B2), FITC-conjugated anti-CD62L (clone MEL-14), PerCP-conjugated anti-Gr1 
(Ly6G/6C; clone RB6-8C5), biotin-conjugated anti–GL-7 (clone GL-7), PE-conjugated 
anti-CD278 (ICOS; clone 7E.17G9), PE-conjugated anti-CD279 (PD-1; clone MIH4), 
and PE-conjugated streptavidin (all from eBioscience, San Diego, CA). PE-conjugated 
anti-CD138 (clone 281-2) and biotin-conjugated anti-CXCR5 (clone 2G8) Abs were 
purchased from BD Biosciences. All flow-based analyses were based on the gating of 
live cells as given by forward and side scatter properties. 
3.2.3 ELISA 
Serum was obtained from NP27-CGG immunized anti-Gr1 Ab and control Ab-treated 
animals before, during, and after treatment. 2HB (Immulon) 96-well microtiter plates 
were coated with 5 μg/well NP5 conjugated to BSA in PBS overnight and blocked for 2 h 
at room temperature with 5% gelatin in PBS. Serum was diluted 1:10,000 in serum 
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diluent (5 μg/ml bovine γ-globulin, 5% gelatin, 0.05% Tween in PBS). A total of 100 μl/ 
well diluted serum was plated and incubated for 2 h at room temperature. All washes 
were done using 0.05% Tween in PBS. Plates were developed using HRP-conjugated 
anti-IgG1 secondary Abs and 10 μg/ml 2,29-azinobis(3-ethylbenzthiazoline-6-sulphonic 
acid) in Mcilwain’s buffer (0.09 M Na2HPO4, 0.06 M citric acid, pH 4.6), and 
colorimetric readings were done at 405 nm on a Victor 3 plate reader (Perkin Elmer, 
Waltham, MA). All samples per experiment were run at the same time, allowing for 
direct comparisons of OD values to determine Ab levels between samples. 
3.2.4 T cell proliferation assay 
Spleen single cells were prepared from 9-wk-old male and female (NZB xNZW)F1 mice. 
Gr1
high
CD11b
+
 and Gr1
low
CD11b
+
 cells were sorted by high-speed cell sorting 
(FACSAria II; BD Biosciences). Total T cells were isolated from female (NZB x 
NZW)F1 age-matched mice by MACS separation using CD90.2 microbeads (Miltenyi 
Biotech, CA). After isolation, T cells were labeled with CFSE (Sigma-Aldrich). After 
labeling, cells were washed and reconstituted in cell culture media (RPMI 1640, 10% 
FBS, 1% Penicillin/Streptomycin, 1 μM Na-pyruvate, 1xMEM). A total of 2 x 105 T 
cells/well were plated in 96-well microtiter plates in the presence or absence of plate-
bound anti-CD3 and anti-CD28 Abs (10 μg/ml each; both from eBioscience). Where 
noted, 5 x10
4
 flow-sorted Gr1
high
CD11b
+
 or GR1
low
 CD11b
+
 cells were added to the 
cultures at time 0 h. After 48 hr, cells were harvested and stained with allophycocyanin-
conjugated anti- CD4 and PerCP-conjugated anti-CD8 Abs (eBioscience), allowing for 
separate analysis of proliferation of CD4
+
 and CD8
+
 T cell subsets. 
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3.2.5 TFH cell differentiation assay 
Naive CD90.2+CD62Lhigh T cells and Gr1
+
CD11b
+ 
cells were sorted by high-speed cell 
sorting (FACSAriaII; BD Biosciences) from spleens of 9-wk-old male (NZB x NZW)F1 
mice. A total of 3 x 10
5
 naive T cells was plated in the presence or absence of 
Gr1
+
CD11b
+
 cells at different ratios (Gr1
+
/T cell ratio = 1:4, 1:8, and 1:16). Cells were 
cultured in cell culture media (RPMI 1640, 10% FBS, 1% Penicillin/Streptomycin, 1 μM 
Napyruvate, 1x MEM) in the presence of plate-bound anti-CD3 and anti- CD28 Abs (3 
μg/ml each), 10 μg/ml anti–IL-4 Ab (eBioscience), 10 μg/ml anti–IFN-γ Ab 
(eBioscience), 20 μg/ml anti–TGF-b Ab (R&D Systems, Minneapolis, MN), 50 ng/ml 
rIL-21, and 100 ng/ml IL-6 (both from Biolegend, San Diego, CA) (29). The media were 
replaced with fresh media containing the same amounts of cytokines on day 3. After 5 d, 
cells were harvested and stained using the following Abs and conjugates: anti–PD-1 
(FITC), biotinylated anti-CXCR5 and streptavidin-PE conjugate, anti-Gr1 (PerCP), and 
anti-CD4 (allophycocyanin; all from eBioscience). TFH cells were identified as 
CD4
+
Gr1
-
CXCR5
+
PD-1
+
 by flow cytometry as previously described (212). 
3.2.6 Immunofluorescence staining 
Two-millimeter slices of spleens were taken from mice on days 3, 5, 7, and 14 
postimmunization and quick-frozen horizontally in OCT (Tissue-Tek, Sakura, CA). Five-
micrometer sections were prepared and stained with biotinylated anti–GL-7/streptavidin-
conjugated allophycocyanin and Pacific Blue–conjugated anti-B220 (all from 
eBioscience). Images were collected using an HC Plan Apo 103/0.7NA objective lens on 
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a Leica DMR upright microscope (Leica Microsystems) equipped with a Retiga EXi 
Cooled CCD Camera (QImaging). Numbers of GCs were counted from three distinct 
fields per spleen and the average number was used for statistical analyses. 
3.2.7 Statistical analyses 
All statistical analyses were performed using GraphPad Prism version 4.00 for Windows, 
GraphPad Software (San Diego, CA; http://www.graphpad. com). Statistical significance 
between the means of two groups was determined using Student t test or the 
nonparametric Mann–Whitney U test as applicable. Analyses of in vivo kinetics of TFH 
and GC B cells were done by two-way ANOVA tests. Analysis of Gr1+ cell– mediated 
suppression of TFH differentiation in vitro was done using the one-way ANOVA test. 
3.3. Results 
3.3.1 Female (NZB x NZW)F1 mice produce more Ab in response to immunization 
than male (NZB x NZW)F1 mice 
To determine whether male and female (NZB x NZW)F1 mice responded differently to 
Ag challenge, 9-wk-old mice were immunized i.p. with NP-CGG/CFA known to elicit a 
strong T-dependent IgG1 response (213). Four weeks post-immunization (day 28), female 
(NZB x NZW)F1 mice produced significantly higher titers of anti-NP–specific IgG1 Abs 
(p < 0.001) than male (NZB x NZW)F1 mice (Figure 3.1A). In a separate study, we 
determined the numbers of splenic GC B cells and PCs in male and female (NZB x 
NZW)F1 mice 2 wk post-immunization (day 14). Female (NZB x NZW)F1 mice 
expressed significantly elevated numbers of splenic GL-7
+
B220
+
CD38
low 
GC B cells (p < 
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0.05) and CD138
+
B220
low 
IgM
low
 PCs (p < 0.05) as compared with male (NZB  x 
NZW)F1 mice (Figure 3.1B, 3.1C). 
 
 
Figure 3.1 Female (NZB x NZW)F1 mice have stronger Ab responses than males in 
response to T dependent Ag. (A) Male and female (NZB x NZW) F1 mice were 
immunized at day 0 with 20 µg NP27- CGG in CFA or control PBS. (A) On day 28, mice 
were analyzed for serum anti-NP5 IgG1 Abs by ELISA. ***p < 0.001, Student t test. (B 
and C) A separate cohort of mice were immunized as in (A) and euthanized on day 14. 
Total number of splenic GL7
+ 
GC B cells and CD138
+
B220
low
 PCs were enumerated. 
Each symbol represents one mouse. *p < 0.05, Mann–Whitney U test. 
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3.3.2. Gr1
+
 cells suppress Ab responses to T-dependent Ag challenge in male but not 
female (NZB x NZW) F1 mice 
We have previously shown that male (NZB x NZW) F1 mice have constitutively higher 
levels of Gr1
+
CD11b
+
 cells, and that depletion of Gr1
+
 cells in vivo reduces the levels of 
antinuclear Abs in male but not female (NZB x NZW)F1 mice (211). To determine 
whether Gr1
+
 cells play a similar role in the NP-CGG/CFA–induced Ab response, we 
treated male and female (NZB x NZW)F1 mice with anti-Gr1–depleting Abs or control 
rat IgG Abs continuously every 3 d starting 1 d before immunization. Treatment with 
anti-Gr1–depleting Ab did not significantly affect other cell populations (Figure 3.2A). 
As expected, depletion of Gr1- expressing cells elevated the anti-NP–specific IgG1 Ab 
titers in male mice as compared with control rat IgG-treated males (p < 0.001; Figure 
3.2B), whereas depletion of Gr1-expressing cells had no significant effect on the Ab 
response in female mice (p = 0.17; Figure 3.2C). When analyzing the splenic 
compartment at 2 wk post-immunization  we found that depletion of Gr1-expressing cells 
resulted in higher numbers of both GC B cells and PCs in male mice (p < 0.05), but again 
with no  effect in female mice (Figure 3.2D, 3.2E). Notably, consistent with their 
autoimmune phenotype, unimmunized female (NZB x NZW)F1 mice expressed 
continuously increased numbers of PCs as compared with male (NZB x NZW)F1 mice (p 
< 0.05; Figure 3.2E). Thus, Gr1-expressing cells suppress immunization-induced Ab 
responses in male, but not female, mice.  
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Figure 3.2(A) Treatment with anti-Gr1–depleting Ab did not significantly affect 
other cell populations. Injection of Anti-Gr1 depletion antibody does not affect non-
Gr1- expressing cell subsets in the spleen. Male (NZB x NZW)F1 mice were injected 
with 500 μg anti-Gr1 antibody (column 2 and 4) or 500 μg rat IgG control antibody 
(column 1 and 3). After 48 hours, spleens were harvested and the relative levels of 
lymphoid- and myeloid derived cell subsets were defined by flow cytometry. 
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Figure 3.2(B-E) Depletion of Gr1
+
 cells augments Ab responses after TD-Ag 
immunization. Male and female (NZB x NZW)F1 mice were immunized at day 0 with 
20 μg NP27-CGG in CFA. Where indicated, mice were additionally treated with an anti- 
Gr1–depleting Ab or control rat IgG every 3 d starting at day -1. Serum from males (B) 
and females (C) was collected every 7 d and tested for levels of anti-NP5 IgG1 Abs by 
ELISA. An asterisk above the graph indicates statistical difference at a single time point 
 
  
 B 
E D 
C 
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(Student t test), whereas the p value inserted at the lower right of the graph denotes the 
statistical difference between anti-Gr1 Ab and control IgG–treated mice over time (two-
way ANOVA test). (D and E) A separate cohort of mice were immunized and treated as 
in (B) and (C), but sacrificed at day 14 post-immunization. Splenic GC B cells (D) and 
PCs (E) were assessed by flow cytometry. n = 5–9/ treatment group. *p < 0.05, Mann– 
Whitney U test. 
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3.3.3 Gr1
+
 cells suppress Ab responses only to T-dependent Ag challenge in male 
(NZB x NZW) F1 mice 
To determine whether the suppressive effect was dependent on T cells, an additional 
cohort of male (NZB x NZW)F1 mice was immunized with NP-Ficoll, a T-independent 
Ag, and treated with either depleting anti-Gr1 Ab or rat IgG control Ab. Depletion of 
Gr1-expressing cells had no effect on the Ab response and B cell differentiation induced 
after T-independent Ag immunization (Figure 3.3A). Also there was no difference in the 
numbers of GC B cells and PCs between anti-Gr1 Ab or rat IgG control Ab treated 
animals (Figure 3.3B, 3.3C). Thus, the in vivo suppressive effect of Gr1+ cells is 
dependent on T cells. 
 
 
 
Figure 3.3 The T-independent immune response in not regulated by Gr1
+
 cells in 
male (NZB x NZW)F1 mice. Male (NZB x NZW)F1 mice were immunized with NP27- 
FICOLL/CFA on day 0. Mice were treated with depleting anti-Gr1 Ab (n = 4) or control 
rat IgG (n = 4) every three days starting on day -1. Serum was obtained every 7 days and 
tested for anti-NP antibodies (A). Total numbers of GC B cells (B) and PCs (C) were 
enumerated from spleens of treated mice upon sacrifice on day 28. 
A C B 
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3.3.4 Male, but not female, Gr1
low
 CD11b
+
 cells suppress T cell proliferation in vitro 
Gr1-expressing cells consist of two major cell subsets expressing high and low levels of 
Gr1, respectively. Both subsets have been shown to have suppressive functions in cancer 
studies (reviewed in Ref. (175)); however, Gr1
low
Ly6C+CD11b+ cells have been 
specifically associated with T cell suppression in another model of lupus (214). We 
hypothesized that Gr1
low
CD11b
+
 cells from male (NZB x NZW)F1 mice could have a 
similar suppressive effect on T cells and hence be involved in the in vivo effect of Gr1
+
 
cells during T-dependent Ab responses. Gr1
high
CD11b
+
 and Gr1
low
 CD11b
+
 cells were 
sort purified from male and female 4-wk-old (NZB x NZW)F1 mice (Figure 3.4A) and 
added to CFSE-labeled MACS-purified T cells in the presence or absence of anti-CD3 
and anti-CD28 cross-linking Abs. Gr1
low
CD11b
+
 cells, but not Gr1
high
 CD11b
+
 cells, 
suppressed T cell proliferation in vitro (Figure 3.4B, 3.4C). Although both male- and 
female-derived Gr1
low
CD11b
+
 cells from 4-wk-old mice functionally suppressed T cell 
proliferation, only suppression by male-derived cells reached statistical significance 
(male: p < 0.01; female: p = 0.056; Figure 3.4D). This difference became even more 
apparent when we compared the suppressive effect of male and female Gr1
low
CD11b
+ 
cells obtained from 9-wk-old (NZB x NZW)F1 mice (Figure 3.4E), and is consistent with 
the differential effect of in vivo Gr1
+
 cell depletion in 9-wkold male and female (NZB x 
NZW)F1 mice as described earlier (Figure 3.2).  
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Figure 3.4 Male, but not female, Gr1
low
CD11b
+ 
cells from 9-wk-old (NZB x NZW)F1 
suppress T cell proliferation in vitro. (A) Gating strategy for flow cytometry–based 
isolation of Gr1
high
CD11b
+ 
and Gr1
low
CD11b
+
 cells. Both populations of cells reached 
>99% purity after isolation. (B) The identification of CFSE-labeled CD4
+
 T cells after 2 
d of culture either unstimulated (none) or stimulated (anti-CD3/CD28). (C) Histogram 
plots showing the percentage of CD4
+
 cells that underwent >1 divisions in culture (gate: 
dividing cells) in the presence or absence of anti-CD3/anti-CD28 stimulation and Gr1
high
 
CD11b
+
 or Gr1
low
CD11b
+ 
cells (4:1 ratio of T cells to Gr1
+
 cells). (D) The average of five 
independent experiments (mean ± SEM) using cells from 4-wkold mice is shown. **p < 
0.01, paired Student t test. (E) Gr1
low
CD11b
+
 cells from male (NZB x NZW)F1 mice 
remain suppressive in 9-wk-old mice, whereas female-derived Gr1
low
CD11b
+
 cells lose 
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their capacity to suppress. Experiments were done as shown in (A)–(D). Bars show the 
mean ± SEM of six independent analyses. *p < 0.05, **p < 0.01, paired Student t test. 
 
3.3.5 Depletion of Gr1-expressing cells during immunization of male (NZB x 
NZW)F1 mice alters the distribution of CD4
+
 effector T cell subsets 
Because the suppressive effect of Gr1-expressing cells after immunization is dependent 
on T cells, and Gr1
low
CD11b
+
 cells specifically suppress T cell proliferation in vitro, we 
expected T cells to be differentially expressed in immunized male (NZB x NZW)F1 mice 
treated with anti-Gr1–depleting Ab or control rat IgG. Contrary to our prediction, total 
numbers of both CD4
+
 and CD8
+
 T cells were unaffected by the absence of Gr1
+
 cells 
(Figure 3.5A, 3.5B). Further analyses showed that the percentage of CD4
+
 T cells 
expressing markers consistent with memory-effector T cells (CD44
high
CD62L
low
), TFH 
cells (ICOS
+
PD-1
+
CD4
+
) were significantly increased in the absence of Gr1-expressing 
cells (p < 0.001, p < 0.01, respectively; Figure 3.5C). T regulatory cells 
(Foxp3
+
CD4
+
CD25
+
) were also increased in Gr1
+
 cell–depleted mice as compared to 
non-depleted mice, but the difference failed to reach statistical significance (p =0.056). In 
contrast, the percentage of naive CD4
+
 T cells (CD44
low
 CD62L
high
) significantly 
decreased (p < 0.01) after Gr1
+
 cell depletion (Figure 3.5C). Thus, Gr1
+
 cells appear to 
regulate differentiation of CD4
+
 T cells during thymus-dependent (TD) Ab responses in 
vivo. 
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Figure 3.5 Depletion of Gr1
+
 cells affects CD4
+
 T cell subsets after antigen 
immunization in male (NZB X NZW)F1 mice. Male (NZB x NZW)F1 mice were 
immunized with NP27-CGG in CFA on day 0 and treated with either anti-Gr1 depleting 
antibody or control rat IgG every three days starting at day -1. Mice were sacrificed 14 
days post immunization and numbers of splenic CD4
+
 T cells (A) and CD8
+
 T cells (B) 
were determined. (C) Activation and differentiation of CD4
+
 T cells were analyzed by 
flow cytometry: memory/effector CD4
+
 T cells were identified as 
CD44
high
CD62L
low
CD4
+
, TFH cells as PD-1
+
ICOS
+
CD4
+
, and Tregs as 
FoxP3
+
CD4
+
CD25
+
. Each symbol represents one mouse. n = 6-7. * p < 0.05; ** p < 0.01; 
*** p < 0.001, Mann-Whitney U test. 
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3.3.6 Gr1-expressing cells inhibit GC formation after Ag challenge 
GC formation is crucial for class switching and production of Abs after immunization, 
and is dependent on T cell help, specifically TFH cells. The increased number of GC B 
cells (Figure 3.2C) and TFH cells (Figure 3.5C) in anti-Gr1 Ab–treated male (NZB x 
NZW)F1 mice 14 d post-immunization suggest that Gr1-expressing cells may also affect 
GC reactions. We tested this by comparing the number of TFH cells and GC B cells, and 
the appearance of GCs in mice immunized with NP-CGG/CFA and treated with either 
depleting anti-Gr1 Ab or control rat IgG. Already at 5 d post-immunization, mice 
depleted of Gr1-expressing cells expressed elevated levels of TFH cells, and at 7 and 14 d 
post-immunization, the levels were significantly higher in anti-Gr1 Ab–treated mice 
(Figure 3.6A). Numbers of splenic GC B cells were similarly elevated in mice depleted of 
Gr1-expressing cells 14 d post immunization (p < 0.01; Figure 3.6B). These data were 
further supported by immunofluorescence staining of spleen sections showing 
significantly elevated numbers and increased sizes of GCs in anti-Gr1 Ab–treated mice 
(Figure 3.6C, 3.6D). 
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Figure 3.6 Depletion of Gr1
+
 cells enhances TFH cell differentiation and GC 
formation in vivo. (A and B) Male (NZB x NZW)F1 mice were immunized as described 
in Figure 3.1. Mice were additionally treated with anti-Gr1 depleting antibody or control 
rat IgG at days -1, 2, 4 and 6. Cohorts of mice were sacrificed at days 3, 5, 7, and 14 and 
analyzed for numbers of splenic TFH cells (CD4
+
PD-1
+
CXCR5
+
)(A) and GC B cells 
(GL7
+
B220
+
)(B). Numbers of TFH cells were compared per time point: * p < 0.05; ** p 
< 0.01; *** p < 0.001, Mann-Whitney U test. (C) Snap-frozen spleen sections from the 
same mice were stained for GC using biotinylated GL7/streptavidin-allophycocyanin 
(APC) and Pacific Blue-conjugated B220. Original magnification X10. (D) Numbers of 
GCs per field of vision were quantified by averaging the count from 3 distinct fields per 
spleen. n = 3-9 per time/point. * p < 0.05; ** p < 0.01; *** p <  0.001.  
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3.3.7 Male (NZB x NZW)F1 Gr1-expressing cells suppress T cell differentiation into 
TFH cells in vitro 
TFH cells play a major role in the formation of GC. Because numbers of TFH cells, GC B 
cells, GCs, and PCs were all significantly upregulated in the absence of Gr1-expressing 
cells, we asked whether Gr1
+
 cells can directly suppress differentiation of naive T cells 
into TFH cells in vitro. Sort-purified male (NZB x NZW)F1 naive T cells 
(CD90.2
+
CD62L
high
) were cocultured with increasing concentrations of sort-purified 
male Gr1
+
 cells for 5 d in TFH cell-skewing media (Figure 3.7A, 3.7B) (212). Upon 
harvest, cells were stained for Gr1, CD4, CXCR5, and PD-1, and the percentage of 
CXCR5, PD-1, double-positive CD4
+
 cells was determined as previously described 
(212). Gr1
+
 cells significantly suppressed the differentiation of naive T cells into TFH 
cells. The suppression was dose dependent and reached statistical significance at 4:1 and 
8:1 ratios of T cells to Gr1
+
 cells (p < 0.01). The suppression of differentiation was not 
due to reduced survival of T cells, as the number of CD4+ T cells recovered on day 5 
improved significantly and in a dose-dependent manner with the addition of Gr1+ cells 
(p< 0.05–0.001; data not shown). Thus, immunosuppressive Gr1+ cells appear to play a 
hitherto unrecognized role in controlling naive T cell differentiation during T-dependent 
Ag exposure.  
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Figure 3.7 Male (NZB x NZW)F1 Gr1
+
 cells inhibit naïve T cell differentiation into 
TFH cells in vitro. (A) Naïve CD4
+
 T cells (CD90
+
CD62L
high
) and total Gr1
+
CD11b
+
 cells 
were flow sorted from 9 wk old male (NZB x NZW)F1 mice by flow cytometry. (B) T 
cells were plated in TFH-skewing media alone or in the presence of Gr1
+
CD11b
+ 
cells at 
the indicated ratios. After 5 days, cells were harvested and stained for CD4, CXCR5 and 
PD-1, indicating a TFH-like phenotype. All cells analyzed were Gr1
-
. The contour plots 
shown are representative of four independent experiments. The mean ± SD per condition 
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is shown in the upper right corner of each plot. The p value given in each plot indicates 
the statistical difference between T cells differentiated in the presence or absence of Gr1
+
 
cells (one-way ANOVA test). 
3.4 Discussion 
The sex bias in SLE and other autoimmune diseases is not well understood. There is 
evidence that sex hormones, both estrogen and testosterone, are involved in the 
differential prevalence of SLE and mouse lupus-like disease
 
among males
 
and females 
(70,72,73,81,169,170). The protective function of testosterone, although well established, 
has not been studied in details and the molecular mechanism through which male sex 
hormone may act is not known. Interestingly, Ab responses to immunization are often 
also higher in females than in males
 
(reviewed in Ref.(210)), suggesting that a generally 
overactive immune system in females might exist and help explain the female sex bias 
observed in many autoimmune disorders, including SLE. 
We have recently shown that male lupus-prone (NZB x NZW) F1 mice have higher 
levels of immunosuppressive Gr1
+
 cells than females, that these cells are driven by 
testosterone, and that depletion of the cells in males resulted in increased spontaneous 
autoantibody production (211). Using the same model, in this article, we describe how 
male (NZB x NZW)F1 mice respond less vigorously than females to TD exogenous Ag 
immunization. Furthermore, depletion of Gr1
+
 cells in (NZB x NZW)F1 males increased 
the Ab response to Ag challenge, along with an underlying expansion of splenic GC B 
cells, PCs, and TFH cells. The main function of TFH cells is to facilitate GC reactions and 
the differentiation of naïve B cells into PCs. Interestingly; TFH cells have been associated 
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with disease severity in lupus patients, as well as several murine models 
(154,161,207,215-218). Thus, we hypothesized that Gr1
+
 cells control Ab production 
primarily via modulation of TFH cells. In support hereof, we found that Gr1
+
 cells 
inhibited the differentiation of TFH cells in vitro in a dose-dependent manner, although 
the mechanism of suppression remains unresolved.  
Gr1+ cells are a heterogeneous population of cells consisting of mature and immature 
neutrophils, immature monocytes, and some dendritic cell subsets. Both proinflammatory 
and suppressor functions have been associated with such cells. In cancer, 
immunosuppressive Gr1+ cells are widely known as myeloid-derived suppressor cells 
(MDSCs; reviewed in Ref.(175)). Despite the identification of immunosuppressive Gr1+ 
cells in several models of autoimmunity (125,126,219-221), during viral infections (123), 
and graft rejection (222), the term MDSC is only sporadically used in such models. 
Whether testosterone-induced Gr1-expressing cells from male (NZB x NZW)F1 mice can 
be classified as MDSCs or represent a different population of immunosuppressive Gr1-
expressing cells in this lupus model remains to be determined. The observation that male 
Gr1
high
CD11b
+
 cells suppress B cells independent of reactive oxygen species, NO, IL-10, 
and TGF-β (211) suggests the cells may not reflect tumor-induced MDSCs (121,223), 
although further molecular and functional studies directly comparing these cell subsets 
are needed to confirm such distinction. 
In nonautoimmune C57BL/6 mice, Gr1-expressing cells have also been shown to affect 
the activation of adaptive immunity after footpad immunizations (224). Specifically, it 
was shown that neutrophils (defined as Gr1
+
Ly-6G
+
CD11b
+
) interfered with the 
activation of T cells through the control of Ag uptake by professional APCs, thereby 
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limiting dendritic cell–T cell contact time in draining lymph nodes (224). Interestingly, 
analyses of Gr1
+
 cells in nonautoimmune mouse strains revealed similarly elevated levels 
in males of most strains, including C57BL/6 (B6), BALB/c, and 129/Sv (data not shown). 
Upon immunization with NP-CGG in CFA, we detected increased serum Ab responses in 
female as compared with male B6 mice (data not shown). Interestingly, preliminary 
analyses showed that Ab-mediated depletion of Gr1
+
 cells in B6 mice drove expansions 
of GC and memory B cells in spleens of both male and female C57BL/6 mice 4 wk after 
immunization, albeit without affecting anti-NP–specific Ab levels (E. Der and T.N. 
Jorgensen, unpublished observations). Thus, Gr1
+ 
cells from nonautoimmune B6 mice 
may exert some, but not all, of the immunosuppressive functions we observe in (NZB x 
NZW)F1 mice. 
Interestingly, for reasons yet unknown, Gr1-expressing cells seem to have a limited 
protective effect in females (Ref. (211)) and this study). In fact, upon aging or during 
active disease, female Gr1
+
 cells become stimulatory as described by us and others 
(113,211,225,226), suggesting that disease-related inflammatory factors present in lupus-
prone females can influence the immunosuppressive function of immature myeloid Gr1
+ 
cells. Identification of such factor(s) clearly represents an attractive new target for 
therapeutic use in SLE and other diseases with dysregulated Ab production.  
In summary, Gr1-expressing cells from lupus-prone male (NZB x NZW)F1 mice 
suppress T and B cell responses, resulting in reduced GC formation and less PC 
differentiation. Discovering the mechanism through which Gr1
+
CD11b
+
 cells suppress in 
the context of lupus could open new doors for immunotherapy of lupus patients and new 
targets for therapeutic agents. 
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CHAPTER IV 
 
INTRINSIC AUTOIMMUNE CAPACITIES OF HEMATOPOIETIC CELLS 
FROM FEMALE NEW ZEALAND HYBRID MICE 
 
Abstract 
Most systemic autoimmune diseases are more commonly found in females than in males. 
This is particularly evident in Sjögren’s Syndrome, Systemic Lupus Erythromatosis 
(SLE) and thyroid autoimmunity, where the ratio of females to males ranges from 20:1 to 
8:1. Our understanding of the etiology of SLE implies important roles for genetics, 
environmental factors as well as sex hormones, but the relative significance of each 
remains unknown. Using the New Zealand hybrid mouse model system of SLE we 
present here new fetal liver chimeras –based system in which we can segregate the effects 
of immune system genes and sex hormones in vivo. We show that female hematopoietic 
cells express an intrinsic capacity to drive lupus-like disease in both male and female 
recipient mice, suggesting that this capacity is hormone independent. Particularly, only 
chimera mice with a female hematopoietic system showed significantly increased 
numbers of germinal center B cells, memory B cells and plasma cells followed by a 
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spontaneous loss of tolerance to nuclear components and hence elevated serum anti-
nuclear autoantibodies. A protective effect of testosterone was noted with regards to 
disease onset, not disease incidence. Thus, genetic factors encoded within the female 
hematopoietic system can effectively drive lupus-like disease even in male recipients.  
 
4.1 Introduction 
Autoimmune diseases such as systemic lupus erythematosus (SLE) have a strong female 
bias (64). A female predominance is also observed in the New Zealand hybrid mouse 
model of SLE ((NZB x NZW)F1), where 100% of females, but less than 40% of males 
develop end-stage renal disease within 1 year of age (70,71) . Lupus-like disease in (NZB 
x NZW)F1 mice is characterized by elevated anti-nuclear autoantibodies (ANA), IgG-
immune complex (IgG-IC) deposition and complement fixation in the kidney glomeruli, 
and glomerulonephritis (GN) resembling the human disorder (227). The disease is 
generally believed to be mediated by immune system defects as shown in bone marrow 
(BM) transfer studies (228).  
Levels of sex hormones or differences in sex-linked gene expression patterns are valid 
explanations for the pronounced sex difference observed (NZB x NZW)F1 lupus-like 
disease. In this regard, prepubertal hormonal manipulation studies have shown a 
protective effect of testosterone and exacerbating effect of estrogens (70,72,73,81,208). 
In addition, exposure to sex hormones during embryogenesis can affect autoimmune 
development in adult mice (229).  
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Genetic overexpression of X-linked genes, as seen in mice carrying the Yaa lupus 
susceptibility locus, has also been strongly associated with disease development 
(161,230). Particularly, a link between copies of Tlr7 and the development of ANA have 
been demonstrated (161,231-233), although other genes expressed on the X chromosome 
likely also play a role, as demonstrated in TLR7-deficient male B6.Nba2(Yaa) congenic 
lupus-prone mice (234). Also supporting an effect of the X chromosome are data showing 
a correlation between pristine-induced lupus-like disease and X chromosome dosage in 
castrated Sry-transgenic male mice and the accelerated spontaneous development of 
lupus in XX versus XY
-
 NZM2328 mice (157).  
Type I interferons (IFNα) play a crucial role in SLE and lupus-like disease development 
(187,235). In (NZB x NZW)F1 mice, elevating the levels of IFNα increases autoantibody 
production and accelerates renal disease onset (236). IFNα can be produced by many cell 
subsets, but most noticeably by plasmacytoid dendritic cells (pDCs) in response to a 
variety of stimuli targeting intracellular toll-like receptors (TLR) 7, 8 and 9 and 
cytoplasmic DNA sensors such as Aim2, DAI/ZBP1, Lrrfip1 and IFI16 (Ifi204) (237-
240). IFNα is known to affect T cells, as well as B cells, although whether one or both 
mechanisms are involved in IFNα-driven lupus-like disease is still unknown (241,242).   
In this study, we investigated whether female hematopoietic stem- and progenitor cells 
were capable of driving autoimmunity in the presence of male and/or female sex 
hormones. Using a unique mixed sex chimera system, we found that female 
hematopoietic cells (HCs) could drive the development of lupus-like renal disease, 
elevated levels of germinal center (GC) B cells, memory B cells and plasma cells, and 
increased ANA in all recipients regardless of sex hormone levels.  In addition, mice 
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receiving female HCs expressed elevated levels of serum IFNα prior to the generation of 
ANA and the onset of renal disease.  Male recipients of female HCs exhibited a delay in 
the onset of disease as compared with female recipients, suggesting that the protective 
effect of testosterone affected early events in disease propagation only. Thus, surprisingly 
the disease-driving capacity of female HCs appears more potent in driving disease than 
the known protective effect of testosterone.   
4.2 Materials and Methods 
4.2.1 Mice and cells 
Three week old male and female (NZB x NZW)F1 mice were obtained from The Jackson 
Laboratory and kept in a specific pathogen-free environment at National Jewish Health 
(Denver, CO, USA). All mouse experiments were approved by the local IACUC 
committee. Bone Marrow chimera mice were generated by lethal irradiation (1000 rad) 
using a Cs
137
-irradiator of 4 wk old male or female prepubertal (NZB x NZW)F1 mice. 
Mice were given acidified water (pH 2.7) to drink throughout the experiment. Bone 
marrow cells were obtained from 4 wk old male or female (NZB x NZW)F1 mice and 
5x10
6 
cells were
 
injected intravenously 2-4 hours after irradiation. Fetal liver single cells 
were obtained from E13.5-E14.5 embryos and frozen in 90% fetal bovine serum, 10% 
DMSO at -80°C. The sex of each embryo was determined visually as well as by real-time 
RT-PCR analyses of Uty and Xist expression levels (see below). Each fetal liver provided 
enough cells to reconstitute 3 recipients via tail vein injection.  
 95 
 
4.2.2 Real-time reverse transcriptase-polymerase chain reaction 
PBMCs were obtained from chimera mice 6 weeks post reconstitution. RNA was isolated 
using RNeasy Plus Micro Kit (Qiagen, Valencia, CA, USA) and cDNA prepared using 
the qScript cDNA SuperMix (Quanta BioSciences, Gaithersburg, MD, USA). PCR was 
run on a real-time PCR machine (ABI7300, Applied Biosystems, Carlsbad, CA, USA) 
using the following primers: Xist-F: 5’-GGAGGAACGAAAGACCAAATTG-3’; Xist-R: 
5’-GTCCCACCCTCTGT GAGTGAA-3’; Uty-F: 5’-
TGCCATCACAAGTCAAAGCAA-3’; Uty-R: 5’-TGGTGCATCCA ACCTAACTGTT-
3’. Unmanipulated male and female samples were used separately or in different ratios 
(1:1, 1:3, 1:9, 1:27) to generate a standard curve. The levels of transcripts in chimera 
mice were calculated as % of total. 
4.2.3 Detection of sex hormones 
Estradiol and testosterone were measured by ELISA using the manufacturer’s protocols 
(US Biological, Salem, MA, USA). Testosterone levels were measured on 10 times 
diluted serum. Estradiol levels were measured after extraction. Briefly, 50 µl of serum 
was vortexed with 500 µl ethyl ether for 30 seconds. Phases were allowed to separate and 
the organic phase was transferred to a fresh glass tube. Solvent was allowed to evaporate 
before the residue was dissolved in 250 µl of extraction buffer.  
4.2.4 Antibody ELISA 
Serum was obtained from chimera mice every 4 weeks starting 8 weeks post irradiation 
and reconstitution. For detection of total IgG and IgM, serum was diluted 1:50.000–
1:200.000 in serum diluent (sterile filtered 0.5% bovine -globulin, 5% gelatin, 0.05mM 
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Tween in 1x PBS). For detection of ANAs, serum was diluted 1:300.  Levels of anti-
chromatin, anti-histone and anti-dsDNA IgG autoantibodies were measured as previously 
described (211). All reactions were developed using 10mg/ml 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid)(ABTS) in McllWain’s buffer (0.09 M Na2HPO4, 
0.06 M citric acid, pH 4.6). Anti-dsDNA IgG levels were determined using the 
manufacturer’s protocol (Alpha Diagnostic International Inc., San Antonio, TX, USA). 
 
4.2.5 Cytokine ELISA 
IFNα and BAFF were measured in 1:4 diluted serum obtained 12 and 16 weeks post 
irradiation and reconstitution, respectively, using the manufacturer’s protocols (IFNα 
ELISA: PBL Interferon Source, NJ; BAFF ELISA: R & D Systems, Minneapolis, MN, 
USA). 
4.2.6 Flow Cytometry 
Flow cytometry was performed using a Cyan Flow cytometer ADP (BECKMAN 
COULTER, Indianapolis, IN, USA) and all analyses were done using FloJo version 9.5.2 
(Tree Star Inc., Ashland, OR, USA). Antibodies with the following specificities were 
used for all analyses: CD11b, CD11c, CD19, CD21, CD23, CD38, CD40, B220 
(CD45R), CD86, CD138, F4/80, Gr1 (Ly6C/6G), IgM, IgD, (all from eBiosciences, San 
Diego, CA, USA). Peanut agglutinin (PNA) was obtained from Vector inc. (Burlingame, 
CA, USA).  
 97 
 
4.2.7 Immunofluorescence staining 
IgG deposition and complement factor 3 (C3) fixation was measured by 
immunofluorescence staining. Briefly, half kidneys were quick-frozen in OCT and 5µm 
sections were prepared. Sections were stained using TexasRed-conjugated anti-mouse 
IgG (Invitrogen, Grand Island, NY, USA) and FITC-conjugated anti-mouse C3 specific 
antibodies (ICL Inc., Portland, OR, USA). Images were collected using an HC Plan Apo 
20x/0.7NA objective lens on a Leica DMR upright microscope (Leica Microsytems, 
Buffalo Grove, IL, USA) equipped with a Retiga EXi Cooled CCD Camera (QImaging, 
Surrey, BC, Canada). 
4.2.8 Statistical analysis 
All statistical analyses were done using GraphPad Prism v. 5.04 (GraphPad INC., La 
Jolla, CA, USA). Analyses of cumulative incidence were done using a Log-rank test 
(Mantel Cox test). Comparisons of average time of onset, cellular proportions, and serum 
cytokine levels between two groups were done using a two-tailed non-parametric Mann 
Whitney test. P values < 0.05 were considered statistical. 
4.3 Results 
4.3.1 Female BM cells transfer renal disease into male and female recipients with a 
higher incidence and faster kinetic than male BM cells 
Estrogens are known to promote lupus-like disease development in (NZB x NZW)F1 
mice, while testosterone has been found to protect against the disease (72,73). In 
addition, X chromosome dosage has been found to affect disease development in other 
mouse models of SLE (157,243) . Since sex hormones affect the immune system 
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(76,244), distinguishing the effect of hormones from the effect of genes has been 
challenging. We asked if female HCs from (NZB x NZW)F1 mice could transfer disease 
into hormonally intact, lethally irradiated, age-matched male recipients. The major male 
antigen H-Y is not presented by H2d and H2z, allowing reconstitution to occur without 
rejection (245).To avoid potential effects of pubertal sex hormones, we performed the 
experiments using 4 wk old, prepubertal mice. Female HCs were capable of driving 
lupus-like renal disease in 100% of recipient mice by 31 wks post transfer, regardless of 
the sex of the recipient mouse (Figure 4.1A). In contrast, within the same timeframe, 
male HCs transferred disease into 57% and 25% of female and male recipients, 
respectively (Figure 4.1A, p < 0.05-0.001). Even when kept until 1 year of age (48 weeks 
post transfer), only ~85% of recipient mice accepting male hematopoietic cells developed 
renal disease (p<0.001). Irradiation and reconstitution itself accelerated end-stage lupus-
like disease development in all recipient mice regardless of sex, although the 
characteristic difference between control male-into-male and female-into-female 
remained statistically significant (p < 0.001). The disease onset was similar in male and 
female mice receiving female BM cells, while M-into-M BM chimera mice started 
developing disease slightly later than M-into-F BM chimera mice (Figure 4.1A, not 
statistically significant).  
The differential disease development was not driven by differences within the stem cell 
and progenitor cell compartment of males and females, as BM samples from 4 wk old 
unmanipulated male and female (NZB x NZW)F1 mice showed equivalent levels of 
hematopoietic stem cells (HSC), common myeloid progenitors (CMP), common 
lymphoid progenitors (CLP), granulocyte-macrophage progenitors (GMP) and 
 99 
 
megakaryocyte-erythrocyte progenitors (MEP) (Figure 4.1B). In addition, all mice 
analyzed had grafted successfully, as noted by the relative expression of Xist and Uty 
transcripts in PBMC fractions from mice receiving female or male hematopoietic cells 
(Figure 4.1C). Moreover, recipient mice continued to express sex hormones at levels 
equivalent to unmanipulated mice as determined by serum levels of estradiol and 
testosterone (Figure 4.1D-E). Thus, female HCs from prepubertal 4 wk old (NZB x 
NZW)F1 mice transferred accelerated renal disease into both male and female age-
matched (NZB x NZW)F1 mice independently of the recipient’s sex hormone 
environment. 
 
Figure 4.1 Female prepubertal BM cells transfer lupus-like disease in a hormone 
independent fashion. Four wk old (NZBxNZW)F1 male and female mice were lethally 
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irradiated and reconstituted with male or female BM cells from age-matched mice. (A) 
Mice were followed for the development of renal disease by detection of proteinuria 
every two weeks. Mice with severe proteinuria (> 100mg/dL on two consecutive 
readings) were considered positive. All mice were euthanized 48 weeks post transfer, 
regardless of disease stage. Female-into-female (open square, n=6); Female-into-Male 
(light grey triangle, n=8); Male-into-female (dark grey triangle, n=7); Male-into-Male 
(filled circle, n=8). (B) BM cells were isolated from 4 wk old mice (n=5 for both males 
and females) and the proportions of hematopoietic stem cells and progenitor cell subsets 
were determined by flow cytometry. (C) PBMCs were isolated from BM chimera mice 
18 weeks after transfer (n=2 of each). Total RNA was isolated and cDNA generated. The 
levels of Xist and Uty transcripts were normalized to the levels of beta-2-microglobulin 
and the % was calculated relative to the levels in control female-into-female (100% Xist) 
or male-into-male (100% Uty) BM chimera mice. (D and E) Serum was isolated from 
BM chimera mice 18 weeks after transfer and levels of testosterone (D) and estradiol (E) 
were measured by ELISA. Female recipient: n=13 (testosterone), n=6 (estradiol); male 
recipient: n=15 (testosterone), n=5 (estradiol); female control: n=10 (testosterone), n=10 
(estradiol); male control: n=6 (testosterone), n¼7 (estradiol). *** p < 0.001. 
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4.3.2 The capacity of female hematopoietic cells to transfer renal disease is present 
in utero 
Sex hormones are produced at high levels starting at puberty. However, even in utero and 
during the postnatal period sex hormones are produced, and hence HCs from 4-week-old 
female (NZBxNZW)F1 mice could have acquired their autoimmune capacities as a result 
of such exposure. To test for this possibility, we generated fetal liver (FL) mixed chimera 
mice. FL cells were isolated from male or female (NZBxNZW)F1 embryos at days 
E13.5–E14.5 and transferred into lethally irradiated 4-week-old prepubertal male or 
female (NZBxNZW)F1 mice. Mice were followed for the development of proteinuria 
until 32 weeks after transfer. Diagnosis of disease was confirmed by discovery of 
elevated colocalized IgG-immune complex deposition and complement fixation in kidney 
glomeruli in chimera mice that had received female FL cells (Figure 4.2D). 
Similar to the experiments involving BM cell transfer from 4-week-old donors, female 
FL cells induced a rapid onset of disease in 100% of recipient mice, while male FL cells 
induced less disease and significantly delayed disease onset (Figures 4.2A and B, 
p<0.001). However, disease occurred somewhat later in male, versus female, recipients of 
female FL cells (Figure 4.2B, p<0.01). Again, we did not find this to be a result of 
differences among the transferred HCs, as analyses of FL cells from male and female 
(NZBxNZW)F1 embryos showed no differences in the distribution of cell subsets (Figure 
4.2C). Similar to the BM chimeric mice, serum level of sex hormones in FL chimeric 
mice were comparable to that of unmanipulated male and female (NZBxNZW)F1 mice 
(data not shown).  
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Figure 4.2 Female FL cells transfer lupus-like disease into both male and female 
recipients with 100% incidence. Four week old BWF1 male and female mice were 
lethally irradiated and reconstituted with male or female FL cells from E14.5 male or 
female (NZBxNZW)F1 embryos. (A) Two cohorts of FL chimera mice were followed for 
the development of renal disease by detection of proteinuria every 2 weeks. Mice with 
severe proteinuria (> 100mg/dL on two consecutive readings) were considered positive. 
All mice were euthanized 35 (cohort 1) or 32 (cohort 2) weeks after transfer, regardless 
of disease stage. Female-into-female (open square, n = 10); female-into-male (light grey 
triangle, n = 12); Male-into-female (dark grey triangle, n = 7); Male-into-male (filled 
circle, n = 4). (B) Disease onset up to 35 weeks after transfer (cohort 1) is shown. 
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Female-into-female (open square, n=5); female-into-male (light gray triangle, n=5); 
male-into-female (dark gray triangle, n=7); male-into-male (filled circle, n=4). Control 
unmanipulated mice are included for comparison: females (open diamonds, n=6) and 
males (filled diamonds, n=6). (C) FL cells were isolated from E14.5 embryos and the 
ratios of stem cell and progenitor cell subsets were determined in male cells (filled 
squares, n=4) and female cells (open triangles, n=6). NS: not statistically different. (D) 
Upon sacrifice of the mice described in (A), kidneys were harvested and analyzed for IgG 
deposition (red) and C3 fixation (green). Pictures shown represent averages per 
condition. Each symbol represents an individual mouse. * p < 0.05; ** p < 0.01; *** p < 
0.001. 
4.3.3 Reconstitution with Female FL cells specifically affects levels of post-activation 
B cell subsets 
Lupus is a B cell and autoantibody mediated disorder. We tested if B cell numbers and 
subset distribution were different between the four groups of FL chimera mice. Gating 
strategies are depicted in Figures 4.3A-D. In spleens, neither total numbers of B cells 
(CD19
+
) nor marginal zone B cells (CD19
+
CD21
high
CD23
-
IgM
high
IgD
low
) were 
significantly different between various FL chimera mice (Figure 4.3 E and G). However, 
mice that had received female FL cells displayed overall increased levels of follicular 
mature B cells (CD19
+
CD21
low
CD23
high
IgM
low
IgD
high
) (Figure 4.3F), regardless of the 
sex of the recipient. Even more strikingly, numbers of germinal center B cells 
(CD19
+
PNA
+
CD38
low
IgM
low
), memory B cells (CD19
+
CD38
hi
IgM
low
) and plasma cells 
(B220
low/neg
CD138
+
IgM
-
) were significantly elevated in chimera mice that had received 
female FL cells (Figure 4.3H-J, p < 0.05-0.01). Consistent with a female-driven effect 
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driving differentiation of mature B cells in the periphery, we found no differences among 
the relative levels of pro-B, pre-B and immature B cell subsets in the bone marrow of FL 
chimera mice (data not shown). 
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Figure 4.3 The female hematopoietic system of (NZB x NZW)F1 mice promotes B 
cell differentiation. Spleens were harvested from FL chimera mice at the time of 
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sacrifice. Samples were analyzed for the presence of B cell subsets by flow cytometry. 
(A-D) Representative plots show the gating strategy used to determine follicular mature 
(FO), Marginal Zone (MZ), germinal center (GC), Memory (Mem) B cells and plasma 
cells (PC). (E-J) Total numbers of indicated B cell subsets are presented per FL chimera 
mouse. Each symbol represents one mouse. * p < 0.05; ** p < 0.01. Brackets in black 
indicate statistical differences between groups receiving male or female FL cells, while 
brackets in grey represent statistical differences between individual groups of chimeras. 
Mice analyzed included female-into-female (n=9, female-into-male (n=11), male-into-
female (n=7) and male-into-male (n=3) FL chimeric mice. 
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4.3.4 Autoantibody production is driven by female HCs and not affected by the 
presence of male sex hormone 
Female (NZB x NZW)F1 mice develop hypergammaglobulinemia at early ages followed 
by a specific loss of tolerance to nuclear autoantigens (199,200). We analyzed whether 
total immunoglobulin and ANA levels were associated with the sex of the FL donor in 
our chimera system. Increased levels of total IgG, IgG1 and IgG2A in the serum of FL 
chimera mice did not correlate with the groups of mice developing renal disease (Fig. 
4A-C). In fact, male-into-male FL chimera mice, which did not develop lupus-like 
disease, had the highest levels of circulating total immunoglobulins. In contrast, the 
levels of anti-chromatin IgG, anti-histone IgG and anti-dsDNA IgG were all significantly 
elevated in chimera mice that had received female FL cells as compared with those mice 
receiving male FL cells (Figure 4.4D-F, p < 0.05-0.001), suggesting that mice that had 
received female HCs displayed a specific loss of tolerance to nuclear antigens. 
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Figure 4.4 Serum anti-nuclear IgG autoantibody levels in FL chimera (NZB x 
NZW)F1 mice are elevated in mice that received female donor cells. Serum total IgG 
(A), IgG1 (B), IgG2a (C), anti-chromatin IgG (D), anti-histone IgG (E) and anti-dsDNA 
IgG (F) levels were measured by ELISA in samples from FL chimera mice at 12 (A-C) 
or 20 (D-F) weeks post irradiation/reconstitution. * p < 0.05; ** p < 0.01; *** p < 0.001. 
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Brackets in black indicate statistical differences between groups receiving male or female 
FL cells, while brackets in grey represent statistical differences between individual 
groups of chimeras. Groups of mice analyzed included female-into-female (n=8–13), 
female-into-male (n=11–13), male-into-female (n=7–8) and male-into-male (n=4–8) FL 
chimeric mice along with 6–9 female and 6 male unmanipulated age-matched controls. 
4.3.5 Levels of serum IFNα, but not BAFF, are elevated in chimera mice receiving 
female FL cells 
Possibly explanations for this observation include an increased capacity of female-
derived B cells to differentiate into autoantibody producing cells or increased levels of B 
cell differentiating signals secreted by female-derived non-B cell HCs. To test the later 
idea, we examined FL chimera mice for levels of serum B-cell-activating factor (BAFF) 
at 16 weeks after irradiation and reconstitution; before the onset of renal disease. B-cell-
activating factor (BAFF) is known to be involved in B cell survival and differentiation 
and has previously been found to be associated with lupus in several mouse models (14-
16,246,247). FL chimera mice that had received female HCs did not express elevated 
levels of BAFF (Figure 4.5A). In fact, male FL chimera mice were found to express 
higher levels of BAFF than female FL chimera mice, regardless of whether these had 
received male or female FL cells (p < 0.05).IFNα is also known to influence B cell 
differentiation (248) and is capable of driving disease development in (NZB x NZW)F1 
mice and related strains (97,236,249,250). We tested serum levels of IFNα in FL 
chimera mice 12 weeks post irradiation and reconstitution, before the onset of renal 
disease. Mice reconstituted with female FL cells displayed higher levels of serum IFNα 
than mice reconstituted with male FL cells (Figure 4.5B, female versus male donor: p < 
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0.05). Furthermore, levels of serum IFNα at 12 weeks after transfer correlated 
statistically with levels of serum anti-chromatin IgG (p < 0.001), anti-histones IgG (p < 
0.05) and anti-dsDNA IgG (p < 0.05) measured 20 weeks after transfer (Figure 4.5C-E). 
Serum IFNα levels measured 12 weeks after reconstitution also trended towards a 
negative correlation with the onset of renal disease in all FL chimeras (p = 0.1, Figure 
4.5F). 
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Figure 4.5 Elevated serum IFNα levels are driven by the female hematopoietic 
system and correlates with early disease onset. Serum was obtained from FL chimera 
mice 12 or 16 week after irradiation and reconstitution. Levels of BAFF were measured 
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16 weeks post transfer (A), while levels of IFNα were measured 12 weeks post transfer 
(B). Levels of IFNα correlated positively with autoantibody levels at 20 weeks after 
irradiation/reconstitution (C-E) and negatively with onset of disease (F). Disease onset 
was defined as the time point where any given mouse presented with severe proteinuria 
(100 mg/dL) for the first of two consecutive readings (also see Figure 4.2). Each symbol 
represents one FL chimera mouse. * p < 0.05. Groups of mice analyzed included female-
into-female (n= 7-14), female-into-male (n= 8-12), male-into-female (n= 6-8) and male-
into-male (n= 3-8) FL chimeric mice. 
4.4 Discussion 
Although tremendous amounts of research have gone into determining the 
etiology of SLE, the underlying mechanism(s) driving disease initiation and/or 
progression are still poorly defined. We and others have previously shown that 
manipulation of sex hormone production from puberty significantly alters the 
development of renal disease (70,72,73,81,208). Specifically, castration of male lupus-
prone (NZB x NZW)F1 mice was found to remove the protective effect of testosterone 
resulting in disease development equivalent to that of female unmanipulated mice 
(70,73). Conversely, ovariectomy of female (NZB x NZW)F1 mice prior to puberty fails 
to alter disease kinetics (73,81), suggesting that after the immune system is established 
in female mice around 2-3 weeks of age, estrogens are not crucial for disease 
progression. Here we have shown that, female HCs are capable of driving lupus-like 
disease in hormonally intact, lethally irradiated male (NZB x NZW)F1 FL recipient 
mice. Thus, even in the presence of testosterone, female HCs from lupus-prone (NZB x 
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NZW)F1 mice cannot be held back and proceed to generate autoreactive B cells, 
followed by IgG-IC deposition, glomerulonephritis and renal failure.  
Pre-B cell lines from fetal livers of lupus-prone (NZB x NZW)F1 mice have previously 
been shown to possess intrinsic autoimmune competencies when compared with pre-B 
cell lines established from non-lupus prone strains (165), however, whether these cells 
lines were of a male or female origin was not reported and remains unknown. As the 
immune system of FL chimera mice originates from transferred stem cells and progenitor 
cells, rather than more mature lymphocytes, our data suggest that the defect is genetically 
encoded. A major player in B cell development and differentiation is Bruton’s tyrosine 
kinase (Btk) encoded by the X chromosome (251). Although not much is known about 
Btk levels and activity in lupus, a recent study reported amelioration of end-stage lupus-
like disease in older female (NZB x NZW)F1 mice treated with Btk inhibitor (252). The 
study did not investigate if males were equally susceptible, and thus any sex-driven 
abnormality remains to be identified. Another candidate gene is Cd40L, also encoded by 
the X chromosome. CD40L is essential for T-cell-dependent B-cell activation and has 
been assigned an essential role in (NZBxNZW)F1 lupus-like disease 
development;(11,253) however, whether CD40L-mediated B-cell activation is 
differentially active in male and female recipients remains unknown. 
IFNα is recognized as a key cytokine in SLE and mouse lupus-like disease 
(97,101,235,249,250,254). IFNα is predominantly induced in response to viral or 
intracellular bacterial infections, but although tempting, a cause-and-effect relationship 
between infections and SLE remains elusive. We observed elevated levels of serum IFNα 
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in chimera mice that had received female HCs, suggesting that dysregulated IFNα 
production, either directly or via exorbitant endogenous stimuli, is also intrinsically 
driven by female HCs. Several genes known to be involved in IFNα production and/or 
responsiveness have been associated with SLE in genome wide association studies, 
including Irf5, Irf7, Irf8, Irak1, Tyk2, Stat4 and Fcgr2a among others (reviewed in 
(255)). Of these, Irak1 is particularly interesting. First, the Irak1 gene is encoded on the 
X chromosome making it an attractive candidate when studying sex-dependent disease 
patterns. Secondly, IRAK1 protein is essential for most TLR-mediated intracellular 
signaling resulting in IFNα production. And finally, IRAK1 has been shown to be 
required for SLE serum (i.e. IgG-IC)-induced pDC activation and IFNα production (256). 
Tlr7 is another X-linked gene that has been strongly associated with mouse lupus-like 
disease (234,243), although not directly identified in GWAS studies. Recently, however, 
TLR7 expression levels were found to correlate with elevated levels of anti-RNA 
antibodies in SLE patients (257). TLR7 is expressed by both pDCs and B cells resulting 
in IFNα production and B cell differentiation (94,258), and TLR7-deficient lupus-prone 
mice fail to develop significant levels of ANAs (243). Whether female pDCs and/or B 
cells respond better to TLR7 cross-linking than male cells remains to be determined, 
however, it is tempting to speculate such a relationship since (1) autoantibody producing 
CD11c
+
 B cells depend on TLR7 signaling and are found predominantly in young 
autoimmune females (233), and (2) TLR7 agonist stimulation of human PBMCs resulted 
in significantly more IFNα production from female, than male cells (259,260). 
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As estrogen receptor expression is required for disease development in female (NZB x 
NZW)F1 mice, it is interesting to note that IFNα induces transcription of the Esr1 gene 
and subsequent expression of the estrogen receptor a (261,262). Oppositely, estrogen 
treatment has been suggested to drive dendritic cell activation and enhanced IFNα 
production upon TLR ligation (263,264). Whether male and female HCs respond equally 
to estrogens has been evaluated both in vivo and in vitro in (NZBxNZW)F1 and non-
autoimmune mice, showing no significant differences (264-266). On the basis of these 
observations, we do not believe that disease–promoting effect of female HCs is because 
of increased responsiveness of female cells to low levels of estrogen present in male 
recipients, although further experiments are needed to firmly rule out this possibility. 
So what about testosterone and its well established protective effect? We have 
recently described the presence of a population of testosterone-induced 
immunosuppressive myeloid cells (Gr1
high
CD11b
+
) in male (NZB x NZW)F1 mice 
(211). These cells have the capacity to directly suppress B cell differentiation in vitro, 
while depletion in vivo promotes autoantibody production in male mice. In our chimera 
system, male recipients experienced a later onset of disease, although autoantibody 
production seemed to be only marginally lower in male versus female recipients. On the 
basis of these observations, we propose that testosterone may act by promoting the 
development of immunosuppressive Gr1
high
CD11b
+
 cells capable of delaying, but not 
inhibiting, disease development. The presence of these cells is subsequently enough to 
control intrinsic disease promoting signals in male HCs, but not in female HCs, the latter 
promoting elevated IFNα production, B cell differentiation, ANA production and fatal 
renal disease. Taken together, we have found that (NZB x NZW)F1 female HCs have an 
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intrinsic ability to drive autoimmune lupus-like disease, regardless of the hormonal 
environment of the host. This strongly implicates genetic rather than hormonal factors as 
the underlying mechanism driving the increased incidence of autoimmunity in females 
as compared to males. 
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Chapter V 
SUMMARY AND DISCUSSION  
 
1.5.1 Summary of major findings: 
The studies in this work are concentrated on delineating the underlying causes for the 
strong female sex-bias seen in the (NZBxNZW)F1 mouse model of lupus-like disease. 
We have laid emphasis on the effect of sex hormones as well as the genetic factors that 
may be responsible for this sex-bias. We have investigated the cellular differences in the 
composition of male versus female immune system and have identified key cellular 
components playing a critical role in the progression of lupus-like disease in these mice. 
Also the relative role of sex hormone versus the intrinsic quality of the hematopoietic 
cells is examined using a unique BM chimera system. The major findings are as follows: 
1. Male (NZBxNZW)F1 lupus prone mice harbor higher numbers of immune-
suppressive Gr1
high
CD11b
+
 cells that suppress B cell differentiation in vitro. 
2. Antibody mediated depletion of Gr1+ cells only in male (NZBxNZW)F1 leads to 
higher levels of auto-antibodies in vivo. 
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3. Female Gr1highCD11b+ cells lose suppressor in post-pubertal age and acquire a 
stimulatory function as the mice get old. 
4. Male and female Gr1highCD11b+ cells use different mechanisms to suppress B cell 
differentiation. 
5. Antibody mediated depletion of Gr1+ cells only in male (NZBxNZW)F1 leads to 
stronger T cell dependent antibody response. 
6. Gr1lowCD11b+ cells suppress T cell proliferation in vitro. 
7. Depletion of Gr1+ cells leads to more TFH cells and germinal centers. 
8. Gr1+ cells suppress TFH cells differentiation in vitro. 
9. Hematopoietic cells from female (NZBxNZW) F1 mice can transfer renal disease 
to male recipients with higher incidence and faster kinetics. 
10. Hematopoietic cells from female (NZBxNZW) F1have disease driving capacity 
in utero. 
11. Auto-antibody production is controlled by the female hematopoietic cells and not 
the host sex hormone levels. 
12. BAFF and IFN-α are elevated in recipients of female hematopoietic cells. 
To summarize, there are multiple factors driving the lupus-like disease in 
(NZBxNZW)F1 mice and we cannot point out a single factor responsible for the sex-bias 
observed in the disease. The presence of testosterone driven immune-suppressive 
population of Gr1
high
CD11b
+
 and Gr1
low
CD11b
+
 in lupus-prone male (NZBxNZW)F1 
with specific suppressor function is a novel finding. The elucidation of suppressive 
mechanism of male Gr1
+
CD11b
+
 can lead to novel therapeutic targets. Also the 
dissection of the testosterone dependent generation of Gr1
+
CD11b
+
 cells can lead to the 
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prospect of enhancing and maintaining these immuo-suppressive cells in female 
(NZBxNZW)F1 mice and modulate the progression of lupus-like disease. Testosterone 
driven immune-suppressive cells protect from the disease but in the BM chimera system 
the female hematopoietic cells take over the protective role of testosterone.  
1.5.2 Discussion and future directions: 
Sex-bias in autoimmunity is a well-studied and well documented phenomena. Our studies 
here try to address the relative contribution of major factors involved in the sex-bias we 
see in the (NZBxNZW)F1 mouse model of lupus-like disease such as immune cell 
composition, sex-hormones and genetic constitution of the immune system. As the 
(NZBxNZW)F1 is a multigenetic  and spontaneous mouse model of lupus with a strong 
female bias, our findings possibly mimic the actual disease as closely as possible in an 
experimental system.  
We have recently witnessed the emergence of various regulatory immune cell subsets like 
Tregs, Bregs and MDSCs. These regulatory cell types are commonly associated with 
immune-suppression which makes them prime targets for therapeutic interventions in 
diseases exacerbated by immune dysregulaiton such as autoimmunity and cancer. The 
role of Tregs and Bregs has been studied in autoimmune diseases but there are no definitive 
studies about their role in lupus. Also the role of MSDCs had been explored in other 
autoimmune conditions like EAE and type I diabetes but not in lupus. It is notable is that 
the effects of all these regulatory cell types have been studied only in the context of T cell 
immunity.  
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Our studies in Chapter 2, report a novel immuno-suppressive Gr1
high
CD11b
+
 (resembling 
granulocytic MDSCs) and Gr1
low
 CD11b
+
 (resembling monocytic MDSCs) MDSC like 
subsets in lupus prone (NZBxNZW) F1 mice. Interestingly, these cells are present in 
higher numbers in male (NZBxNZW) F1mice as compared to female (NZBxNZW) 
F1mice. It is to be noted that we have shown that the number of MDSC like cells are 
regulated by testosterone in (NZBxNZW) F1 mice; but it is not clear that the 
functionality of MDSC like cells described here are regulated by testosterone or not.  It 
has been shown in studies that myeloid progenitors express androgen receptor but we 
have not been able to detect androgen receptor expression on myeloid progenitors in the 
(NZBxNZW) F1 mouse model. We speculate that BM stromal cells may be responsible 
for regulating the number of MDSC like cells in response to testosterone.  Further studies 
are needed to elucidate the exact mechanism of testosterone mediated regulation of Gr1
+
 
CD11b
+
. Additionally, it needs to be addressed that if testosterone affects the Gr1
+
 
CD11b
+
 cells directly or the effect of testosterone is mediated through a myelopoiesis 
promoting cytokine. 
We show that Gr1
high
CD11b
+ 
cells suppress cytokine mediated B cell differentiation in 
vitro and that in vivo depletion of Gr1
+
CD11b
+
 lead to elevated production of auto-
antibodies and kidney disease in male (NZBxNZW) F1. Gr1
low
 CD11b
+ 
cells
 
fail to 
suppress B cell differentiation indicating the presence of two functionally distinct subsets 
of Gr1
+
CD11B
+
 expressing cells. The antibody used to deplete Gr1
+ 
CD11b
+
 cells in vivo 
in our studies depletes both Gr1
high
CD11b
+ 
as well as Gr1
low
 CD11b
+ 
cells, hence we 
cannot delineate the in vivo function of the two Gr1 expressing cell sub sets. To examine 
the specific role the Gr1
high
CD11b
+ 
and Gr1
low
 CD11b
+ 
cells in vivo we have to develop a 
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system where we can specifically deplete either of the cell population. It is to be noted 
that there is a lack of cell surface and morphological markers distinguishing the 
functional role of Gr1
high
CD11b
+ 
and Gr1
low
 CD11b
+ 
cells. 
There are contrasting reports regarding the role of MDSC like cells in the pathogenesis of 
autoimmune diseases. The cell surface markers defining MDSC like cells (Gr1 and 
CD11b) are expressed by neutrophils, monocytes, and macrophages; these cell types are 
inflammatory in nature. The pro-inflammatory and disease promoting role of MDSC like 
cells in lupus-like disease development cannot be overlooked, but our studies show a 
protective role of MDSC like cells in lupus prone (NZBxNZW) F1 male mice. We also 
observed that Gr1
+
CD11b
+
 cells +acquire an inflammatory phenotype as the female 
(NZBxNZW) F1 male mice age.  Hence, we speculate the existence of multiple cell 
subsets with in the Gr1
+
CD11b
+ 
cells with specific functionality and regulatory 
properties. The lack of cell surface markers and functional assays to determine smaller 
cell subsets within the Gr1
+
 CD11b
+ 
cell population presents a challenge to distinguish 
between the immune-suppressive and inflammatory cell types.    
Our  report is the first showing a direct immune-suppressive effect of Gr1
high
CD11b
+  
MDSC like cells on B cells, and that the activity is crucial to the role of Gr1
high
CD11b
+
 in 
mediating the progression of lupus-like disease in (NZBxNZW) F1 mice as B cells are 
the source of pathogenic antibodies. Also the elevated level of serum IL-10 after Gr1
+
 
cell depletion can contribute to the progression of lupus-like disease. The role of IL-10 in 
development of autoimmunity is debatable but it has been shown that IL-10 can promote 
B cell differentiation. The source of IL-10 producing cells in the absence of Gr1
+
CD11b
+ 
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is not known and further investigation is required to identify the cellular source of IL-10 
in (NZBxNZW) F1 mice. We conducted studies described in Chapter 2 to examine the 
role of IL-10 as an immune-suppressive mechanism but our results indicate that IL-10 is 
not acting as an immunosuppressant. Finally, the protective role of testosterone in the 
development of lupus-like disease in (NZBxNZW) F1 has been well established since the 
1970s but the underlying mechanisms are not clear. The regulation of immune-
suppressive Gr1+ CD11b
+ 
cells via testosterone may explain, at least in part, the 
protective role of testosterone in (NZBxNZW) F1 mice.  
Another interesting observation is that the Gr1
high
CD11b
+
 cells from female (NZBxNZW) 
F1 mice lose their suppressive ability post-pubertaly and hence female mice are 
unresponsive to in vivo depletion of Gr1+ cells as the treatments begin at 9-12 weeks of 
age. This time period coincides with the increase in female sex hormone (estrogen) levels 
and the beginning of disease progression, and chronic inflammation in female 
(NZBxNZW) F1 mice. The loss of suppression could be attributed to increased female 
sex hormones or the chronic inflammatory milieu present in female (NZBxNZW) F1 
mice. As discussed in chapter 1, estrogen has an aggravating effect in driving lupus-like 
disease in (NZBxNZW) F1 mice and there is chronic inflammation going on in the form 
of elevated IL-6 and IFN-α level in female (NZBxNZW) F1 mice. We therefore cannot 
rule out either possibility, but it requires further experiments to firmly establish factors 
responsible for loss of suppression by Gr1
high
CD11b
+
 cells in post-pubertal female 
(NZBxNZW) F1 mice. We should also mention that the Gr1
low
 CD11b
+ 
cells become 
stimulatory towards naïve B cells as the mice age which may be due to exposure to 
inflammatory cytokines like IFN-α and induction of NETs. Also the Gr1low CD11b+ cells 
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are very close to low density granulocytes (LDGs) in cellular morphology and granular 
properties, and can further contribute to disease progression in older (NZBxNZW) F1 
mice. It has been shown in human studies that NETs act as a source of auto-antigen for 
progression of autoimmunity. The loss of immune-suppressive function by female cells 
may also be attributed to the intrinsic genetic components of the female immune system.   
Further studies are required to explore the loss of immune-suppressive ability of female 
cells. Reversing the loss of immune-suppression by female Gr1
+
CD11b
+
 cells may be an 
attractive target for therapy. Our studies show that the number and function of 
Gr1
+
CD11b
+
 is differentially regulated in male and female lupus prone mice. These 
differences seem to be a combined effect of sex hormones as well as the genetic 
properties of the immune system. 
The fact that female Gr1
high
CD11b
+ 
cells use classical suppressive mechanisms (ROS and 
iNOS) associated with cancer MDSCs while the male Gr1
high
CD11b
+ 
cells use an 
unknown suppressive mechanism indicates the intrinsic difference in the male and female 
Gr1
high
CD11b
+ 
cells. We have conducted studies aimed at identifying the suppressive 
mechanism used my male Gr1
high
CD11b
+ 
cells. One of the most promising candidate 
genes which were found to be upregulated in male Gr1
high
CD11b
+ 
cells was S100A8/9 
(unpublished data). There have been many studies defining the immune-regulatory role of 
S100A8/9 proteins on the function and accumulation of MDSCs in cancer models. This 
difference may be attributed to the multigenetic nature of (NZBxNZW) F1 mouse model 
and needs further investigation. Moreover elucidating the suppressive mechanism used 
by male Gr1
high
CD11b
+
 cells may present novel therapeutic targets for manipulation in 
SLE. 
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Another interesting observation is that the proportion of male (NZBxNZW) F1 
developing lupus-like disease (~30%) resembles the proportion of male (NZBxNZW) F1 
that have relatively lower levels of Gr1
+
 CD11b
+ 
cells as compared to disease free male 
(NZBxNZW) F1 mice. This observation is potentially interesting as the level of these 
cells can be used as disease predicting bio-marker in susceptible individuals. There is a 
requirement of further studies to examine the possible correlation between Gr1
+
 CD11b
+ 
cells and development of lupus-like disease in (NZBxNZW) F1 mice.  
Since we used a T cell free system to test in vitro suppression of B cell differentiation, the 
next question we asked is whether the in vivo effect on antibody secretion is a direct 
effect of Gr1
+
CD11b
+ 
cells on B cells or if it is mediated through T cells. To address this 
question we used an immunization approach (described in Chapter 3).  
Here we show that female (NZBxNZW) F1 mice respond better to a T dependent 
immunization as compared to male (NZBxNZW) F1 mice. This is in line with the fact 
that female (NZBxNZW) F1 mice have a hyperactive immune response. Next we showed 
that depletion of Gr1+ cells only after immunization with a T cell dependent antigen lead 
to a substantially strong antigen-specific immune response in male (NZBxNZW) F1 
mice. As observed earlier, the females did not respond to anti-Gr1 treatment. These 
findings suggested that in vivo suppression antibody production by Gr1+ cells is 
mediated through T cells. The enhanced antigen specific immune response was 
accompanied by elevated levels of PCs and GC B cells.  
In chapter 1 we described that only Gr1
high
CD11b
+ 
cells are capable of suppressing B cell 
differentiation in vitro; here we found out that only Gr1
low
CD11b
+ 
cells were able to 
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suppress T cell proliferation in vitro. A similar loss in suppressive function of 
Gr1
low
CD11b
+ 
cells was observed in the case of older females. Hence, we have 
established the specific suppressive role for the two separate Gr1 expressing populations 
in lupus-prone (NZBxNZW) F1 male mice. Additionally, both cell subsets lose their 
immune-suppressive capability in post-pubertal female (NZBxNZW) F1 mice.  
Further, depletion of Gr1
+
 cells lead to an increase in effector T cell subsets in 
immunized animals. As discussed in section 1.5, TFH cells are essential for GC formation 
and generation of an antigen-specific antibody mediated immune response. We found that 
that Gr1
+
 cell depletion leads to a rapid increase in TFH cells in vivo after immunization 
and correlated with the increase in germinal center B cells. Indeed, we showed that Gr1
+
 
cells can suppress naïve T cell differentiation into TFH cells. Again the suppressive 
mechanism used by Gr1+ cells to suppress TFH differentiation remains unknown and 
further investigation is required elucidate it. 
We can clearly state that testosterone regulated Gr1+ CD11b+ cells paly a protective role 
in lupus-prone (NZBxNZW) F1 male mice but they are functionally different in female 
(NZBxNZW) F1 mice. We can speculate that these cells have distinct inherent qualities 
and affect the progression of lupus-like disease in a different manner.  
Genetics is one of the major factors contributing to the sex-bias observed in SLE and 
other autoimmune diseases. The hyperactive state of the female immune system and often 
X chromosome dosage are responsible for the female predominance in autoimmune 
disorders. The studies in Chapter 4 show that the power of female (NZBxNZW) F1 is 
enough to overcome the protective role of the testosterone driven immune-suppressive 
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Gr1
+
 CD11b
+
 population. Testosterone in intact male recipients was only able to mildly 
delay the onset of the disease without any effect on the end stage renal disease. The 
ability of the female hematopoietic cells to maintain high levels of lupus driving IFN-α 
irrespective of the hormonal environment of the host indicates the strong genetic pre-
disposition of the female cells to drive lupus-like disease.  In fact, we can speculate that 
the immune-suppressive Gr1
+
 CD11b
+ 
cells can protect lupus prone male (NZBxNZW) 
F1 from disease progression due to the lack of a disease driving genetic program, as the 
females. Additionally, identification of disease driving cell types in the female 
hematopoietic system can also provide therapeutic targets.  
To summarize, we can say that the sex-bias in lupus-like disease development in 
(NZBxNZW) F1 mice is an outcome of multiple factors. We have identified a 
testosterone driven Gr1
+
 CD11b
+ 
cells immune-suppressive cell population which 
protects lupus prone male mice from disease. The female microenvironment comprising 
of female sex hormones as well as the pro-inflammatory cytokines may be responsible 
for fewer numbers and loss of suppression of Gr1
+
 CD11b
+ 
cells. Also the differential 
function of Gr1
+
 CD11b
+ 
cells indicates towards an intrinsic difference between male and 
female immune system. Also the BM chimera system shows the overpowering role of 
female immune system and genetics on the development of lupus-like disease.  
Our studies open exciting avenues for therapeutic targets in terms of unknown immune-
suppressive mechanism used by male Gr1
+
CD11b
+
 cells to regulate lupus like disease 
development in (NZBxNZW) F1 mice. Further, elucidation of testosterone mediated 
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upregulation of Gr1
+
CD11b
+
 cells and the use of Gr1
+
CD11b
+
 cell levels as a disease 
predictive bio-marker.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Relative contribution of different factors in sex-bias of SLE. The strong 
female sex-bias seen in SLE is the outcome of multiple factors working together. 
Genetics play an important role in the form of X linked gene expression and higher levels 
of disease promoting IFN-α production. Sex hormones play another crucial role as 
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estrogen promotes SLE and testosterone has an immune-suppressive function and protect 
from SLE. Lastly, we defined immune-suppressive MDSC like Gr1
+
 cells upregulated in 
lupus prone male mice which can further explain the sex-bias observed in SLE. 
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